<SEC-DOCUMENT>0001415889-12-001389.txt : 20120920
<SEC-HEADER>0001415889-12-001389.hdr.sgml : 20120920
<ACCEPTANCE-DATETIME>20120920134432
ACCESSION NUMBER:		0001415889-12-001389
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20120920
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120920
DATE AS OF CHANGE:		20120920

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ChromaDex Corp.
		CENTRAL INDEX KEY:			0001386570
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				262940963
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53290
		FILM NUMBER:		121101686

	BUSINESS ADDRESS:	
		STREET 1:		10005 MUIRLANDS BLVD.
		STREET 2:		STE. G, FIRST FLOOR
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618
		BUSINESS PHONE:		949-419-0288

	MAIL ADDRESS:	
		STREET 1:		10005 MUIRLANDS BLVD.
		STREET 2:		STE. G, FIRST FLOOR
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92618

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CODY RESOURCES, INC.
		DATE OF NAME CHANGE:	20070112
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cdxc8ksept202012.htm
<TEXT>
<html>
<head>
    <title>cdxc8ksept202012.htm</title>
    <!--Licensed to: secconn26-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">FORM 8-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported) September 20, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">CHROMADEX CORP.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">000-53290</font></div>
</td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">26-2940963</font></div>
</td>
</tr><tr>
<td valign="top" width="32%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation)</font></div>
</td>
<td valign="top" width="23%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td valign="top" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10005 Muirlands Boulevard, Suite G, Irvine, California, 92618</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of principal executive offices, including zip code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(949) 419-0288</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Registrant's telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Copies to:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Harvey Kesner, Esq.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sichenzia Ross Friedman Ference LLP</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">61 Broadway, 32<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">New York, New York 10006</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Phone: (212) 930-9700</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><br>
[&#160; ]&#160;&#160;&#160; <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>[&#160; ]&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>[&#160; ]&#160;&#160;&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

<div>&#160;</div>

<div>[&#160; ]&#160;&#160;&#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 7.01&#160;&#160;&#160;&#160;&#160;&#160; REGULATION FD DISCLOSURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September 20, 2012, Chromadex Corporation (the &#8220;Company&#8221;) issued a press release with respect to certain test results pertaining to the impact of pterostilbene on blood pressure and other metabolic parameters in adults that were announced on September 20, 2012 by the American Heart Association, the abstract of such results is attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 99.1</font>.&#160;&#160;A copy of the press release is attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 99.2</font> and is incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information disclosed under this Item 7.01, including <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 99.1</font> and <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit 99.2</font> attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act, except as expressly set forth in such filing.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 9.01&#160;&#160;&#160;&#160;&#160;&#160; FINANCIAL STATEMENTS AND EXHIBITS</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibits</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit No.</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Description</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%" style="TEXT-ALIGN: left">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="89%" style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Abstract of the Impact Of Pterostilbene On Blood Pressure and Other Metabolic Parameters In Adults, dated September 20, 2012</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="89%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#cceeff">
<td valign="bottom" width="9%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99.2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dated: September 20, 2012</font><br>
</div>

<div>&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="45%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" width="29%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CHROMADEX CORP.</font></font></td>
<td width="26%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="45%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="26%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="45%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160; </font></td>
<td width="24%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Frank L. Jaksch Jr.</font></td>
<td width="26%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="45%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name:&#160; </font></td>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Frank L. Jaksch Jr.</font></td>
<td width="26%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="45%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="5%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Title:&#160; </font></td>
<td width="24%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></td>
<td width="26%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
    <!--Licensed to: secconn26-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div style="TEXT-ALIGN: center"><img src="aha.jpg" alt=""></div>

<div align="center">
<table bgcolor="white" cellpadding="5" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Presentation Abstract</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>&#160;</div>
</td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Session:&#160;</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13-Poster Session II</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thursday, Sep 20, 2012, 1:45 PM - 3:30 PM</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Presentation:</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">617 - <font style="FONT-WEIGHT: bold">Impact of Pterostilbene On Blood Pressure and Other Metabolic Parameters In Adults</font></font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Location:</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Regency</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pres. Time:</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Thursday, Sep 20, 2012, 1:45 PM - 3:30 PM</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Category:</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nutrition and Hypertension</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Keywords:</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Hypertension; Clinical trials; Lipids</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Author(s):</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">Daniel M Riche</font>, Univ of Mississippi Sch of Pharmacy, Jackson, MS; David Deschamp, Michael E. Griswold, Univ of Mississippi Medical Ctr, Jackson, MS; Corey L. McEven, Cleveland Clinic, Cleveland, OH; Krista D. Riche, St. Dominic Hosp, Jackson, MS; Justin J Sherman, Univ of Mississippi Sch of Pharmacy, Jackson, MS; Marion R. Wofford, Univ of Mississippi Medical Ctr, Jackson, MS</font></td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Abstract:</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: justify">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Objective:&#160; Pterostilbene is a polyphenol that is chemically related to resveratrol and commonly found in berries, such as blueberries.&#160; The purpose of this trial was to evaluate the effect of pterostilbene on metabolic parameters.</font></div>

<div>Methods:&#160; The trial was a prospective, randomized, double-blind, placebo-controlled study of patients with a total cholesterol <font style="TEXT-DECORATION: underline">&gt;</font> 200 mg/dL and/or LDL&#160;<font style="TEXT-DECORATION: underline">&gt;</font> 100 mg/dL.&#160; Patients were included if they were <font style="TEXT-DECORATION: underline">&gt;</font> 18&#160; years old and on either no cholesterol therapy or cholesterol medication at a stable dose for at least 2 months prior to baseline laboratory.&#160; Patients were excluded if they had significant hepatic, renal or GI tract disease or current overt cardiovascular disease; were receiving thiazolidinediones or fibric acids; were women who were pregnant or of reproductive potential.&#160; Eighty subjects were divded equally into one of four groups: (1) pterostilbene 125 mg twice daily; (2) pterostilbene 50 mg twice daily; (3) pterostilbene 50 mg + grape extract (GE) 100 mg twice daily; (4) matching placebo twice daily for 6-8 weeks.&#160; Patients received identical couseling on lifestyle intervention.&#160; Metabolic endpoints included blood pressure, body weight, and lipids.&#160; Linear mixed models were used to examine changes in metabolic parameters over time within treatment groups and compare changes over time across groups.&#160; Models were adjusted for age, sex, and race.</div>

<div>Results:&#160; The majority of pateitns completed the study (73/80; 91%).&#160; The average age was 54 years.&#160; The majority of patients were female (57/80; 71%), Caucasian (56/80; 70%), and had HTN (44/80; 55%).&#160; Both systolic (-7.8 mmHg; p&lt;0.01) and diastolic blood pressure (-7.3 mmHg; p&lt;0.001) were&#160;reduced with high dose pterostilbene.&#160; The only change in lipids was an increase in LDL with pterostilbene monotherapy (24.9 mg/dL; p&lt;0.001) which was not seen with GE combination (p=0.47).&#160; Presence of a baseline cholesterol medication appeared to attenuate LDL effects.&#160; Patients not on cholesterol medication (n=51) exhibited minor weight loss with pterostilbene (-0.59 kg/m2; p=0.014).</div>

<div>Conclusion:&#160; Pterostilbene reduces blood pressure in adults.&#160; Future studies should evaluate high dose pterostilbene with GE in a hypertensive population.&#160; Clinicaltrials.gov identifier NCT 01267227.</div>
</td>
</tr><tr>
<td width="18%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Disclosures:</font></td>
<td width="2%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="80%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: justify"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="FONT-WEIGHT: bold">D.M. Riche</font>: B. Research Grant (includes principal investigator, collaborator, or consultant and pending grants as well as grants already received); Modest; Chromadex: Principal Investigator.&#160; <font style="FONT-WEIGHT: bold">D. Deschamp</font>: None.&#160; <font style="FONT-WEIGHT: bold">M.E. Griswold</font>:&#160; None.&#160; <font style="FONT-WEIGHT: bold">C.L. McEwen</font>: None.&#160; <font style="FONT-WEIGHT: bold">K.D. Riche</font>: None.&#160; <font style="FONT-WEIGHT: bold">J.J. Sherman</font>: None.&#160; <font style="FONT-WEIGHT: bold">M.R. Wofford</font>: None.</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center">OASIS Helpdesk</div>

<div style="TEXT-ALIGN: center">Monday-Friday, 9 am - 5 pm CT</div>

<div style="TEXT-ALIGN: center">Phone: 1-217-398-1792</div>

<div style="TEXT-ALIGN: center"><img src="oasis.jpg" alt=""></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex99-2.htm
<TEXT>
<html>
<head>
    <title>ex99-2.htm</title>
    <!--Licensed to: secconn26-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 99.2</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Clinical Study Showed a Blueberry Antioxidant, pTeroPure<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> (pterostilbene), Significantly Reduced Blood Pressure in Adults</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">- Efficacy Data for ChromaDex<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>&#8217;s Patented pTeroPure<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Presented at American Heart Association&#8217;s High Blood Pressure Research 2012 Scientific Sessions -</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IRVINE, Calif. &#8211; September 20, 2012 &#8211; </font>ChromaDex<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> Corporation (OTCBB: CDXC) announced today findings from a Phase 2/3 trial at the University of Mississippi Medical Center showing its patented nutritional ingredient <font style="DISPLAY: inline; TEXT-DECORATION: underline">pTeroPure</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; TEXT-DECORATION: underline">&#174;</font> (pterostilbene) significantly reduced blood pressure in adults. The findings from the study, the first clinical trial of the pure compound, were presented today at the American Heart Association&#8217;s <font style="DISPLAY: inline; TEXT-DECORATION: underline">High Blood Pressure Research 2012 Scientific Sessions</font>.<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">1</font> pTeroPure, which was named the <font style="DISPLAY: inline; TEXT-DECORATION: underline">2010 North American Most Promising Ingredient of the Year</font> by the independent research company Frost &amp; Sullivan, is a nature identical form of pterostilbene, an antioxidant found in blueberries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We saw reduced overall blood pressure in patients who received the high dose of pterostilbene,&#8221; said the study&#8217;s principle investigator, Daniel M. Riche, PharmD, Cardiometabolic Clinic Coordinator at the University of Mississippi School of Pharmacy. &#8220;The results of this study highlight that pterostilbene is a promising ingredient in the area of cardiometabolics.&#8221;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pterostilbene is believed by many experts to show great promise for supporting heart health<font color="black" style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">,<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">2</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">3</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">4</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">5</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">6</font></font> cognitive function,<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">7</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">8</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>anti-aging,<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">9</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">10</font>&#160;weight loss and other metabolic disorders. Pterostilbene has superior biological activity,<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">11</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">12</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">13</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">14</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">15</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#160;</font>better oral bioavailability<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">16</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">17</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">18</font> and metabolizes more slowly in the body than other antioxidant polyphenols (substances from plants that tend to prevent or neutralize the damaging effects of free radicals), resulting in more prolonged antioxidant activity.<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">19</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">20</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">21</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">,</font><font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">22</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The study, a <font style="DISPLAY: inline; TEXT-DECORATION: underline">double-blind, placebo-controlled trial</font>, included 80 adults averaging 54 years of age with high cholesterol (total cholesterol of 200 or greater and/or LDL cholesterol of 100 or greater). Most participants were women (71%) and some had been diagnosed with high blood pressure (55%). The mean average baseline systolic blood pressure (BP) was 127.4 mmHg and the mean average baseline diastolic BP was 79.3 mmHG. The American Heart Association guidelines state that &gt;119 mmHg systolic BP and &gt;79 mmHg diastolic BP are classified as pre-hypertensive.<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">23</font> Twice daily, participants received high (125 mg) doses of pterostilbene, low (50 mg) doses of pterostilbene, pterostilbene (50 mg) with grape extract (100 mg), or placebo. The investigators assessed participants&#8217; blood pressure, body weight and blood lipids at the beginning and end of the study.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By the end of the study, participants in the high-dose pterostilbene group (250 mg/day) achieved significant reductions in BP compared to placebo: 7.8 mmHg in systolic BP (p &lt; 0.01) and 7.3 mm Hg in diastolic BP (p &lt; 0.001), without serious adverse events. The only change in lipids was an increase in LDL cholesterol with pTeroPure (24.9 mg/dL, p &lt; 0.001), which was less among participants on cholesterol-lowering medication and was not seen among those who also received the grape extract. Participants not on cholesterol medication also achieved a minor average reduction in body weight (reduced body mass index 0.59 kg/m<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">2</font>) with pTeroPure. ChromaDex plans to conduct further studies specific for weight reduction to evaluate this trend.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;With high blood pressure affecting more than 76 million adults in the U.S.,<font style="FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">24</font> we are thrilled that these findings show pTeroPure to be effective at reducing blood pressure,&#8221; said Frank Jaksch Jr., CEO and co-founder of ChromaDex. &#8220;With limited&#160;&#160;non-prescription options to address this &#8216;silent killer,&#8217; these results will allow pTeroPure to carry a claim of being &#8216;clinically proven,&#8217; an attribute that should have a meaningful impact on demand for the ingredient.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">pTeroPure is the key novel ingredient in <font style="DISPLAY: inline; TEXT-DECORATION: underline">BluScience&#8482;</font>, ChromaDex's recently launched line of dietary supplements. BluScience, is now available in more than 17,000 outlets in the U.S, including national drugstore chains, wholesalers and mass channel and internet distributors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About ChromaDex<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food &amp; beverage, animal health, cosmetic and pharmaceutical industries. ChromaDex's pipeline of proprietary products include patented pTeroPure<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> pterostilbene, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost &amp; Sullivan. The company has also launched ProC3G&#8482;, a natural black rice extract containing 40% cyanidin-3-glucoside and is in the process of developing Nicotinamide Riboside, a novel next-generation B-vitamin. All products are backed with extensive scientific research and intellectual property. For more information about pTeroPure, visit www.pteropure.com or call 949-600-9694.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-1-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Forward-Looking Statements:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ChromaDex Media Inquiries:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chandler Chicco Agency</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Keshia Cain, Media Specialist</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">310-309-1017</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">kcain@ccapr.com</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ChromaDex Investor Contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">The Del Mar Consulting Group, Inc.</font></font></div>





<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">Robert B. Prag, President</font></font></div>





<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">858-794-9500</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">bprag@delmarconsulting.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">or</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Alex Partners, LLC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Scott Wilfong, President</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">425- 242-0891</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Scott@alexpartnersllc.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ChromaDex Contact:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Laura Carney, Executive Assistant</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">949-419-0288</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">laurac@chromadex.com</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: justify; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="center">
<table bgcolor="white" cellpadding="5" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="100%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.</font></font></td>
</tr></table>
</div>

<div><br>
<hr>
</div>
</div>
</div>
</div>

<div><a name="ref.ID0EOE">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">1</font> Riche DM, Deschamp D, Griswold ME, McEwen CL Riche KD, Sherman JJ, Wofford MR. Impact of pterostilbene on metabolic parameters in humans.&#160;&#160;Poster presentation at: American Heart Association 2012 Scientific Sessions on High Blood Pressure Research.</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EIG">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">2</font> Rimando AM, Nagmani R, Feller DR, and Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem. 53, 3403 (2005).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0E5G">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">3</font> Pan Z, Agarwal AK, Xu T, Feng Q, Baerson SR, Duke SO, Rimando AM. Identification of molecular pathways affected by pterostilbene, a natural dimethylether analog of resveratrol. BMC Med. Genomics. 1, 7 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EUH">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">4</font> Pons L. Agricultural Research/November-December 2006. This work is part of Plant Biological and Molecular Processes(#302) and Quality and Utilization of Agricultural Products (#306), two ARS National Programs described on the World Wide Web at www.nps.ars.usda.gov.</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0ELAAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">5</font> Mizuno CS, Ma G, Khan S, Patny A, Avery MA, Rimando AM. Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha. Bioorg. Med. Chem. 16(7), 3800 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EBBAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">6</font> Park ES, Lim Y, Hong JT, Yoo HS, Lee CK, Pyo MY, Yun YP. Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. Vascul Pharmacol. 53, 61 (2010).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-2-</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div><a name="ref.ID0EVBAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">7</font> Joseph JA, Fisher DR, Cheng V, Rimando AM, and Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J. Agric. Food Chem. 56, 10544 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0ELCAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">8</font> Shukitt-Hale B, Lau FC, Joseph JA. Berry Fruit Supplementation and the Aging Brain. J. Agric. Food Chem. 56, 636 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EDDAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">9</font> Joseph JA, Fisher DR, Cheng V, Rimando AM, and Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J. Agric. Food Chem. 56, 10544 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EZDAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">10</font> Shukitt-Hale B, Lau FC, Joseph JA. Berry Fruit Supplementation and the Aging Brain. J. Agric. Food Chem. 56, 636 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0ENEAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">11</font> Rimando AM, Nagmani R, Feller DR, and Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem. 53, 3403 (2005).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EDFAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">12</font> Perecko T, Jancinova V, Drabikova K, Nosal R, Harmatha J. Structure efficiency relationship in derivatives of stilbene. Comparison of resveratrol, pinosylvin and pterostilbene. Neuro. Endocrinol. Lett. 29(5), 802 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EZFAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">13</font> Joseph JA, Fisher DR, Cheng V, Rimando AM, and Shukitt-Hale B. Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J. Agric. Food Chem. 56, 10544 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EPGAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">14</font> Billack B, Radkar V, Adiabouah C. In vitro evaluation of the cytotoxic and antiproliferative properties of resveratrol and several of its analogs. Cell. Mol. Biol. Lett. 13, 553 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EFHAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">15</font> Meng XL, Yang JY, Chen GL, Wang LH, Zhang LJ, Wang S, Li J, Wu CF. Effects of resveratrol and its derivatives on lipopolysaccharide induced microglial activation and their structure activity relationships. Chem. Biol. Interact. 174(1), 51 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0E4HAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">16</font> Asensi M, Medina I, Ortega A, Carretero J, Carmen Bano M, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33, 387 (2002).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0ETIAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">17</font> Roupe KA, Remsberg CM, Y&#225;&#241;ez JA, Davies NM. Pharmacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol. 1, 81 (2006).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EJJAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">18</font> Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. (2010 Nov 30. Epub ahead of print).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0E4JAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">19</font> Asensi M, Medina I, Ortega A, Carretero J, Carmen Bano M, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 33, 387 (2002).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0ETKAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">20</font> Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. (2010 Nov 30. Epub ahead of print).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EJLAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">21</font> Remsberg CM, Y&#225;&#241;ez JA, Ohgami Y, VegaVilla KR, Rimando AM, Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother. Res. 22, 169 (2008).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0E6LAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">22</font> Ferrer P, Asensi M, Segarra R, Ortega A, Benlloch M, Obrador E, Varea MT, Asensio G, Jord&#225; L, Estrela JM. Associationbetween pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 7, 37 (2005).</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EJNAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">23</font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#160;</font>Based on Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the complete JNC 7 report. Hypertension 2003;42:1206&#8211;52.</font></div>
</div>

<div style="TEXT-ALIGN: justify"><a name="ref.ID0EEPAC">&#160; </a>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">24</font> American Heart Association. Statistical Fact Sheet &#8211; Update 2012. High Blood Pressure <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.heart.org/idc/groups/heart-public/.../ucm_319587.pdf</font>. Accessed September 18, 2012.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">**END**</font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>aha.jpg
<TEXT>
begin 644 aha.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!G`D8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHIEQ<1VL#RRND<4:EW=SA5`Y))/0"@!]%>%_$;_`(*6?`[X8O<17WQ#
MT.^N;5S&]OI3-J4A<,JL@$`<%U+<J#N^5N,J0/F+]I+_`(+U>'8/"]U9_";P
M_?:[J-W&T,&L:N&L=/M';;MD*@&1D"EV+-Y87RV)R1M8`_0K3-3MM;TVWO;*
MX@N[.[B6:">&02131L`RNK#AE((((X(-3U\??\$*/&/B+QI_P3@\)R^(Q<R2
M65]?V5A<S+(#=VD=RXC<;PI*CYD&```@&!C%?8-`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!117(^/?C[X'^%FH1VGB;Q?X
M:\/W,O\`JXM1U&*V>3C.%#L,G&.!S\R_WAD`ZZOQX_X+*_\`!0C6/'/QI\4_
M#72+O4++POX"'EWEJ+*YB35KPA&WRD)F6&/9<1[4(R9$<"0@*?U'\(?M7_##
MQ]>?9M&^(7@S4+O:7-M%K$!G"J`6)C+;P`#SQQWKX._8+_X)^VEU_P`%0/VA
M=?\`'NCPW:^#?$RW^@07,)DBOC?$WL-\V1Y<A1#%@JNY9UF+'=@T`?`.J?!O
MQ[HWP\A\2WOA3QII_AN2`V=MKEWI[0V]WYA>.(Q-<A"))%$;$H'1$\UU*MN4
M<SX>7PYJ^E%_%7BC4?#7AV&R>2XO]HU)I1N63`"RLK3$'S,R3CSA&6>4$;Y/
MU0_X*??\$]OBW_P4'_:]T'3-(U/0_#7PR\+^%H)AK&I^?<&+4[FXOEG%O:1L
MJSR+'!9,3(\00,O,H9HQ%\-O^"2?[/7[,>O0:G\5?B-;>+K^V>:=;'Q!J5MI
MFG>:4C+,+56#.!'`O[J1Y$POW>!@`^G?^">/C.S\>?LG>%]0T3P5>^!/"+0[
M/#-A?3K+=W6F`#R;R8*,*TYWR``MN5T?<=^![;7%?#_X\?#KQDL&G>%O&/@S
M4_(2*&*TTS5;:4Q*RGRT$:,2N54[5P.%..E=K0`4444`>=?M8?M0^%OV,OV?
M_$/Q)\9O?CP_X;CB:>.Q@$]W</+,D,44,>1YDCR2(JJ#DDUSG["O[?'P[_X*
M*?!VX\;_``VO=0NM(LM0?2[J.^M?LUS:W"Q1RE'3)QF.:-@<D%7!'!!K\X?^
M#E7XC:I^U-^TO^SQ^R)X2U%8+_QEK]KKGB#;*W[F*:1[.T+J@8E8U-[<L&&%
M^SQOR54')_X(\(__``3-_P""V'QF_9=>\N?^$&\>V_\`;7@YIW\T7LD-NMS$
MXEVJID>S:ZC81J$W:;+C[F``?LY17X^?%/\`;H_;"^.O_!9/XV?LU?!OQEX6
MTC2])T\M87>L:-"8O"%M]CTN9[XNL)DN)O,N3''&69!]M5G^XH'`?LK?MG_M
M\?'?]HSXH?LG:=\3?`!^(O@R\DGU'XA:IH@)TBQM)$CN/LR1VZP7+W$EU:!!
M)"C0IYAVDLCH`?N%17Y)_P#!+S_@LS\2?!]]^TQX#_:?U>W\5^)/V<])OM=N
M=8TC3X8_M4&GRO;7D!:*.&*0F81^2WE1E@SE]N,+\]Z/_P`%/OVQ?CY\)-0^
M.>F?M,?L]^`8HEN[[3OA!*^FKJ<UI;L<^9'<IYY<XEP#<1AQ%&=P+E:`/WPK
MS_\`:C_:@\%?L9?`G7OB5\1=5ET/P;X96)]1OH[*>\-N)9DA0^7`CR',DB#A
M3C.3Q7Y>_ME?\%\OB!<_\$I_@G\>/A;/X;\-^(/%7BN3P_XNT][,:I'9RV]O
M<//%$)"K(K/%&REE+B.=#@X),'[0O[1W[:G@_P#8H^.WQX^+^F?#C2?A_J?A
MS2;[P5X&U"QLM4M])FFUFP$37T$D1=Y_LTIRC7#(LJY"AMNP`_67X.?%K0?C
MY\)?#/CGPK>2:AX9\8:7;:UI-V]M+;-=6EQ$LL,GERJKKN1U;#*#STKI*_*S
M]J/_`(+"^.?V2?\`@F7^RA_PKSPCX-O_`(S?M`:%IL.E::ED;;1M,9K6U\\P
MVL)7YA/=P)'%E8QN=F(6/:U/1?VD_P#@H)_P3R_:!\`0_'+3--_:"^%_C>_-
MIJ=UX`\(W5_?^%(2Z!II#9VR.#$CF3:\,JRI#*!*),4`?J_17YN?MC?&G]N7
MXR?MB^(OA_\`"3_A!OV>_A9X<MVFM?B#XOM;>\D\0N@B#B&-S.N"S2;4:&([
M(W<R9`C;R?\`81_X+?\`QF^('P,_:K\-^.7^'GBOXE_L\^!=5\1Z-XJT"`OH
MGB&6PCN8W:4+(@DC::&*0/$(=Z2/F*+"!P#]>Z*_$7X>?\%(O^"BG[8'[#.L
M?&[X>VWPCT3PEX#%]/J$SZ:T>K>*Q;.[2BSM'-S&BPH-KK)+&6=#LD(R!^C/
M_!';]O;4O^"D?[!_ACXG:YIFG:3K]S<76F:I#I^Y;62XMI3&TL2.S/&D@"N$
M9F*[L;F&&(!]0T444`%%%%`&!\0OB=HGPLL=,N-<O191:QJMIHMF?+9S-=W4
MJPPQ_*#C<[`9/`ZDUOUX3^WI$+CP_P#"V-KA;56^)_AMC(S!<[;U7"#)&2Y4
M)C.?FZ'H?=J`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBOG#_@J]^TA?\`[,/[$OB?6=&N!::]K3PZ#IMRT9D%I)<ML>?:K`EH
MX1,Z@'ET0<`D@`^1_P#@J#_P5HU^_P!?\5?#SX2W&K6D&B17-E=>)-*G0&6]
M1#OV2H_F);PLLR/)&`WFPN-RK%)G\X]1U>*/5;B\B6:74+YSYD<]SY,]Q.4=
MWB9UC9F\PPK*-\K(^'+;``\<%II\$NAVLX-C:VVF2--Y=J\"6L)A"F+R&C5B
M[X>/+$.O/RX50JR6LLMK9*9XY);(7,FEF.&<7ET5A+"-GCZ3R*-@_=-M+P.=
MQ"J&`/6/@_\`L3_%K]IGP9:^)_A%X&@\1Z/IEY)9F1/$&DK]CNXVC=$F1[J.
M2(A#;W*H\;.#*K-N.VOO+_@FA?\`[9GP"^*5AX3^*WPV\6^*/AMJD8MQJESK
MN@RW/A:3S%"3$KJ!>2U\O<#!&CO%M&TN``WQM^S!_P`%$OB3^QYX1U+PWX5U
M*WETS^T#<31W6E0DS7$ENB*?/QL8LT0P0S91=JJHA"/])_LU?MK?MF?MDZGJ
ML7PYU;X--/HB(U]!KXDMDB1W4(\;6L-PLI,;%F5Y(2"BX!#9H`]T_P""HOQ4
M_:GN_$47@SX$_"OQ5?>'9;)FU7Q78:EHMO++)(A"PVPNKQ94"$JSN8,G#!">
MI_-7XL_\$_\`X]_#[1=9\0^*_A/K^A>'=+BB%SJ6H:KINHRI$TJ+,FZWU!I)
M#(SHL?EPL[>6A*<8/V=^TA^U1^W'^QO\.1XK^(DGP-BT2ZU6#2XDTB:YO[YV
MD#,!$KV\*LVR)R2W0LV$(4$_./[1?_!4SXH?M.?!+5O!/B&[\.OH^M2S1WYA
ML3;31Q6Y2484%Y`X!4D&,A9(R<LD4N0#YPTC5B9+>=[B^1;!98HI%GABD@`G
M<>6J!"T?**FY8\+*V#M(Q7W-_P`$\_\`@L'KWPD\6V7A'XI:X^L>"+FZ@T[3
MM3NE,MSHRR(IBW7"@^='EBI\QW?Y&V,XC<#X2O;RXGL;V)=ZW60CP6DJ-))&
MP,D;*RD[HEC,C$Q.`#$@3:65F<TZZ7=ZAY]U-9::9/M4CN8YI(0'V&41!8T4
M[7D=T5%8=65A&4`!_2O87\&JV,-U:S17-M<QK+%+$X=)4895E8<$$$$$=<U+
M7QK_`,$0OCY<_%G]DAO#NI7/VG4?A_?-HX8G(-N%#1!3SE4RT8Y'"#"JNS/V
M50!^+EA_P1@\6_\`!5+_`(*C?'OQ[^TOX+\7>#OAI/MLO":B\LTN-3BA98+5
MHVC,I1$@A:4JZ`E[LYR0U<I^W=_P0,\4?\$[/B]\'?BQ^QOX7\6^,=0\,Z[)
M?:]I4E_;27L;1/;S6S0DI"/L[QQ7-M,I<DI.@5&RQ7]'_CY_P67^#?[-_P"V
MMHGP#\1_\):/'FO7.E6MM]FTG?8AM1F$-N3,7&1N)W;%8@*W!VD#ZN=BJ$@%
MB!G`ZF@#\O?V)_V5?BIH7_!Q%\:?C-K_`,/O%&B?#WQMX*(T[7+R>-;=YY(M
M!`M=BR%]P%K(&#JI#0#@!%`;_P`$\_V/?BI\+/\`@X-_:9^)?B7P+K.C?#[Q
M;I-]'HFOW!A>VU-Y+G2741LC$@E8)#@JIVQ*&W,I(^G/V!?^"QOP8_X*3_$#
M7O#7PQNO$ESJ/AVP&I79U'2FM(C"9%C!5BQR=S#C`X.:^J:`/QI_9B_X)@_$
MSXC_`/!1O]NZU\:>$=;\+>!?C=H'B;0=%\1W-LBVMU]LU!6@DBP6W@(^_P"8
M`G8W!'3YD^&7[$_C#X"_!Z_^&/C_`/X)H77Q>^,EG)<VNG>.%OB^C:R)9&*W
M-S=1,$78``H,B-M"\QEF"_T8T4`?B%_P43_X)@_%>+_@D)\"_!OACX,:"OQ$
MB\6SZ_XJ\/>`+2X6RTLSZ?=Q[@SRRRY7=;+)B0JS[PA`V$??/_!:OX.>*?C[
M_P`$AOB/X2\%^&=3USQ7JNFZ9_9^C6%H#=.T=]:2R1I&.%81)(.H`P1[5]B4
M4`?C+^V%_P`$[OC/K_\`P3N_8@^)W@+P5J=Y\5OV:M(T:34/!S0"+4R5%@[+
M%$_R[X)K09C;G8[$'*;6]&M?^"@G[8G_``40_:"^&'A3X9_!KXG_`+,_A&QU
M!9_B'XA\4:+;R"6W60B>SMGO;4@'RXW"2)'YADFB+(B*Q/ZJ5P=[^U+\,=-^
M,:_#JY^(W@.W^(+[-OAB37[1-9;>@D3%H9/.^9"&'R\J01Q0!^(W[1G[,GB/
M1O\`@KU\6O&W[3G[*GQD_::\&:U=.G@"7PW!=:E8:;#%,K1HL2.L.U[?:/*F
MD4*T,BA96DW&I^PM^Q%\6])N_P!NNZF_9_\`&/PLM?'WPE\2Z?X7\-'072T$
M\K2R6VG63Q8BF;;(D:[27)7*$*!G^@"B@#\V?^"/GP(\>?"S_@A%XI\'^)_!
MGB;P_P",+BS\5&#0KW3)K?4)#<?:&A5+:55P7WKM11M.1W+5TG_!LW\(/&'P
M*_X)9Z)X:\<>#O$O@;7[+7M1>33->T^:QO=KNCB0QRPQ-M)9L-AMV,[V)./T
M"HH`****`"BBB@#P?]OLQ'PE\,UE4D-\4/"^T@J"&&I1$'YO<=N3GBO>*\(_
M;\E>+P7\-RCNF?B?X44[5)W`ZK`"">P__5WKW>@#S;]LFZN;+]D'XJS6<S6U
MW#X/U=X)5)4Q.+*8JP(Z$'!K^/'3/VC?B#-X2M';QQ\1$LY[,HX?7KQX@I@#
MGYVEV<)OX9<_*IQ@`O\`V&?MGW`L_P!CSXL2EXXQ%X-U=]T@RBXLICD^U?Q<
M^&XD73+6!4MF*6ENDRX\I-P$>&D4CG&[A@`0QW9#J10!^LO_``:N_%?Q1XQ_
MX*@ZE8:MXI\7ZG9M\/-2F:VO=3N+F`NEWINT.KN5+(LI^8Y*EPNQ>2/Z+*_F
MI_X-*9'D_P""J=^Q%Q(!\-]6ARQRJ%;[3"2J;<1@!HP0IP6;;N/E_-_2M0!\
M4_\`!P]XMUCP-_P2#^+6JZ!J6K:3J]I'IK6]SIMZ]G<(3J5J&Q(CHRY4L.&'
MXXVG^9E?VOOB[;VMQ#:?%CXH,MK"5N/)\7:JP.-JY9?/(.\LKAF"G:I."I"U
M_2I_P<GVHO/^"+?QG0N%"P:;+@JS!BFJ6C@$+DGE00,8)`&5SN'\LL!47BQH
MT<OEKYJ>6YEB4N=L9_=`8)C\LXWL1\IRRM\P!^]__!HO\8/%/Q6T?]H#_A*?
M&/C+Q7<6-WH30KK>IW-]%:"1=1),/G.YC9RN74$8VI\HQD^^?\'0_P`3O$OP
MF_X)C1ZIX4\0>(/#.IR^--(LVOM'U.;3KA8I6E5E,T3HRH<@'Y@#T)YKY<_X
M,TK5[+1?VBE)0Q_;=!B7^)P434!@N5!<!60*0S+M5=H4$%_HK_@[#B^T?\$I
M!&?]4_C?1?,!&0P$DA`]LD`?CWZ$`_`RV_;?^-]K)(/^%U_&>R;YIWM+CQUK
M4;S*7,BR$BXW!29&E[.P.<?.!5F+]O[XX6TUO`_QU^-^&B"1,_Q!UL).FY26
M@C^T<?ZQ5(!PIC=@2"H'C4KM!IPNYU:*"59;J$%O.RNXMMBW%G#[B6R_.`-I
M.2M?J%_P1:_X(&>"O^"H7[)^J_$S7_B/XW\,ZM;>)KO1/LVG0VTL""**VFWK
MYJ$Y+2KP1@&/C&YBP!\42_M^?'AX"'^/WQR\N^#%E/Q#US"`R*"S2&Z8?>&-
MX0AF0`@9KN/AE_P63_:E^"^HG^R/CK\0YGCN))?^)W?MK<=R!RXS>_:?E5"^
M,D$!/55W?J;J?_!G+\.)=)OXK/XW?$6*ZN(R(9+G3K*>))`/E=T`4L-V2RHZ
M;P0,C:I'XZ_\%"?V)/%__!.3]J36OA;XSN[76+K2HHM2LM5T[?:1:G93O(+:
MYC&XM&_R,ICRQC>%MKL,$@'[._\`!&#_`(.3KK]K3XPZ/\'OC1IFF6?BWQ!-
M):^'_%6E&.*PUJ555DAF@5G6&1P542(Y1Y7"!$RH/Z^5_$2^MWG@V\34]*N$
MMM6TIEU:SN(FW@W=MB6)E+,>=W(4_?"`@,,5_:Y\-O$+^+OAUH&JR-ODU/3;
M>[9L`;C)$KD\<=^W%`'\^?\`P<4_MN_&;X+?\%4O%F@>"?B[\4O"?A_2O#6D
M7":3H7B74+"R2:2&1Y&,<+JB;@BY8#.6)S\K;?B<_P#!4?\`:#>.TDC_`&A/
MCG/#)F27RO'5_O9<;F*$R8*E!P<'![`@B7Z(_P"#H;9%_P`%A_$QE$Z;_">B
M&,B4LQPDQ+(GR]"!P&)4AV'#,I_/37]5EL-'=D>]>53+<IFX9#*"&.\Y`V+E
M1U;A5P590`H!]()_P4^_:-FD2'_AH#XQJ6#,J+XUU%6(5F50SM.=I88['E6S
MEMB27;/_`(*D_M'Z-/#>)^T)\9TDTYUDFDN/$UVT7&20\<SL@0D)]]`%W-N^
M0C;^B7A[_@T$NO&'@G3K^V_:,!MM6M;:Z6*7P0P/EL@81NPOPSJH(`#``CAE
MXKS#]M;_`(-7_B]^S_\`#76O&/@#Q]H_Q4CTF.>YO-'CT:72=8:TC02![4B:
M83W.5;Y`T)8\AR[<`''_`+*'_!SE^TE\`O&=M_PG5YI7QG\)PAC?6&HP6VEZ
MEM=V13;75NGR^653_7QR[_-V9!/F)^\W[`W[?'P__P""C7[/UE\0OA[?O-8O
M)]DU&PG*B[T>["([6\P4E=VR1'5E)5T=6!(-?R`:-JKZO9M):2%XY2TD4CD2
M2(S!@6&`0#CRU*$`JRC.WDG]%?\`@V=_:DU7X#_\%*M#\(RZB(/"WQ=L+G2;
MZ"]O?*C>\ABEN;.XC4$QR3NT;1X`#.+HL'8*=P!^GW_!SE^T=XT_9@_8"\,>
M(/`GB[Q'X+UR[\>Z?IQO]$U%[*XDB>TOFDB++PR%4)PW`9$;JH(_#73/^"M7
M[2E]=M$OQ\^+ID5_)9'\17`\Z9MNV-=IY^>0(-@))51D9(K]E_\`@[K9HO\`
M@E_H;I+'&1X]TY760.4F4VUY\A"D`_/L;!/1">,9'\\$$<LIN5,4,SJFTM(I
ME!X.(@X)1DVAP-J[N"%5?O4`?2^F?\%;?VE+[RIA^T#\58;<$@+)K3AAE&;;
MN9@"<,#E^`0G8L5MQ?\`!73]IJ"R&/CU\38IEA9IGEU5F6")F^1FWLH+\`9!
MY'/REA'7K'_!+'_@A=KG_!6#]G?Q)X]T?XJ:3X#ATCQ!<Z$+&Y\,&^>61+>S
MF67Y;F/RLI,N3R=T94HC;C7TA??\&@'Q!2UG2V^//A'<RX4IX6NK82]``0+M
MMH&U#QGD'IDY`/CKP!_P6_\`VKOAAJEL^F_&WQ?.?-B1[37K.TU>.8AC(8I#
M<1M(@*I@F,AV#`ANN/TD_P""7/\`P<[VWQG\?Z)\._C]8:%X?UG69!96'B[1
M4ECTNXN245(;N!BYM69GV^8)&BW-'G8'X_)O_@HO_P`$S_BM_P`$O/B#H6A_
M$:'2;K2?$4,KZ9XAT<-<:9J0B'[V.0/&C?:``A,;#.PEMSC=Y?@R&:]AN+?[
M/;N9O,`B5<&)]C8?;M))P&4!/N;EP3N`H`_M=J*_OX-*L9KJZFBMK:VC:666
M5PB1(HRS,QX``!))Z8KY'_X(0_M":I^TG_P2R^%VM:]J2ZKK^DV]UX>U"X\U
MI9)&L;J6VB,CL=SRM!'"SL?O,S'H17U7XR\*VOCKPAJNB7_F&QUBSFL;CRVV
MOY<J%&P>QPQP:`/Q@T/]OS]KK_@N'^T7XSTC]F+Q7;_"+X,^$C]G&N3V\4<F
MH$M(8)I;EH)I=TODDB&V\LI&ZEV.XA;'[5/AW_@H1_P2#\('XLS_`!YT_P".
M7@#3+NV3Q!;7VEEA96[S!-\MO)OF2$-(JM-;3F105)C958G]-?\`@G__`,$\
M/AW_`,$U?@]J'@CX;)K?]CZIJLFL7$NKWWVVZ>9XHHL&4J"4"0IA3TR?6OA3
M_@X6_P""Q?PS\+_LW>,?V>O!&IV'CWXC?$6R;0=3ATR9+FW\/6DYV3&1QE7O
M'7,<5NI+AW#MM5?F`/IG7/\`@H!#^U3_`,$1_B'\>?`-[>^%M6/PS\0:I"T<
MB&Y\/ZK9V%SYB!_F4M#<Q,`V#G:#@=!]1_!_5)]<^$OA:]NI'FN;S2+2>61V
M+,[M"C,23DDDD\FOST^!/[(/BC]BW_@V7^)O@7Q?%Y/BR;X6^,-7U"R!9382
MWEC>W`MF.3AT615?;A0X?:`,5YY_P7Q_;4^*7['_`.R)^S-J7PO\<ZIX'F\0
M(T5_+8>2SW21Z9%)&K>:CQ&-?G8DD8P#RH;`!^GG[0_[1/@S]E/X/ZUX\\?Z
M_8>&_#&@6[3W-W=2!=Y`)6*)?O2S.1M2-`7=B%4$D"OY<_C9_P`%GOV@OB[\
M8?%WBC1?C#\2/#6B^(-:O+[3='M];>(:'!+<3/9VOE+A/W,04%`6.Y#@MDM7
MBWQL_:$\??'J>TU/Q[XW^(7C6^M$\NP;Q#K-WJ45H2WS>6ER653M?><+E?-7
M;P50<+?IOTY8$CN2BQM%'&L$*J90IP9G7YBJJ"Q<*S`X))V**`/ZM?\`@A]\
M4/$_QG_X)<?"WQ-XSUG4/$/B?5$U-K_4+V=YI[ETU6\C!9WPQPJJ!GH`!T%>
MP_MB?M>^!_V%?V>O$'Q,^(6IMIOASP_$"PC3S+B]G<[8;:%/XI97(102`"<L
M54,P^=O^#=NZ6^_X(\?!^9-GDR1ZIY>W<,A=5O%)PP'\2MR!\WWN2Q)^&O\`
M@[[^-6L#6_@M\-[<2Q:)-!J7B6X92'6>[0);6ZD`%DVI)<+YF1CSSCD94`^9
M_P!JW_@Y+_::_:"\3WK^!O$%C\(_#%]YQTG2M'L;2]U)XT?,;S74ZNSM\A+"
M)8/E)`RK!AX)_P`/;?VGHKA;B#X]?%B5&F6-6.K22HHR"SM$%)/4ILR,$+SU
M\SPSX<_#_4OC;\7?#O@O1V?^TO$^N:=H5J%M5D-Q<75W!;QY&[RV0/\`.0X$
M8(VD;6.[^FW7O^#?7]E?6/V5IOAA%\+?#UC+)I[6R>+8K53XG6X*8^UG4#FX
M=]^'*,YC.`NS8`H`/QR_9F_X.6OVEOV=O&&GKXO\2Z1\4O#,96.72-=AAM[V
MX0-DB&^MX_,68KC)E2<!7SL!1S7[_?L&?MO>$/\`@H/^S7H?Q)\'BZM+;4U,
M-]I=Z`M[HUVAQ+:SJ#PRGHPX=2K#AA7\?=I!>Z<LU@7B6:S62":*56@3?&ZB
M0+O#_-\S94#)D?;RXR/WI_X-`)2O[-_QJ@7[2D0\86TJ)*N,[K")=_4\L$''
M'09Y)H`_7^BBB@`K\_?^#B:_O--_99\!3P-"MI%XT0W0DF2,LITZ_157<0`S
M.P4,>A<#@L&7]`J^9?\`@KY\$[SXW_L%^,K?3#='4_#L:Z_;1VX!DG^SY,J#
M)'S&%I=I#+AMIW#&:`/P_P!5E.H7,\[&^U6V\YIHM3MH);="Q58I)"9`J1[P
M`Y=L'YH-I(215J:G)?B6.W33[A_MZ)"Z7&Z*VO(YY`=UQ"6976=D&0^YO]'4
M,`NWS+^EQ1:=I;V3FZL=7V+NE@U")&MYMZ>6WF!=T*F5I$#.K-\ZN^X8`H36
M=EJ$]XVF"&;R8=FRTO-XB9VF\UE@$@<HJ!49-VWY6C(6.2,$`?;VQN+1;L6#
MR6NIW<<TUO&R2(&D&]+8R#;O7.UOWF)`P`'RN<_<W_!OSXEN-(_:O\7::LP&
MEZOX94O&L?EJU['.AV*`!O\`*BW(9#P?D"``.3\3)%J4[:AMEM%6=)9([RUE
M7,X*ME5=))$:&4QY=3*8UVIEF9@:^KO^"(FKR:%^WEX?M=]\O]K^'[]9#<ZB
MDCS9AAEP8,+)$,0IA7+-\KXRJAR`>_?\'&/B2RMO!'PRTJ1C->SW6HWALRQ\
MNXM8XHA,&`'4EXHP<A1YK%BH`:OS'O=7T_74\J*REDWM:VI$UO\`:8KY&DVK
M$4R\(_U"HH)7+)#@@K\WZ&?\'&0Q\0_A<8KF[@G;1M6C`MW1G)>:S1,0LN92
M9&5`BR#>TBJ5()Q^>L<#7UQ(MK'';CR_M#(I\UFA;]VL(5AA90KJ#M0HV)4^
M]M6@"%@(71KJ![2\GACN&ECA1%N$F;>P6)H,O"_FQHA<@1+<A@(V<O&)J5BD
MTUC<OX71;P,AMF8"*Z09DD(52OG*?*B^56*QC/WG#-!;@CAM)X[<VPB6.>61
MK%3(R7$DA4P.X8Y=8T1'<+DN%>1V,CA%=#;6]SHUH]UJ4H2&:&#,U\25@D94
M2X=0&90RE20[1JLAW(!&"7`/T:_X-Z[V['B[XG6LEK):K'8Z:LBF-PY"^:(1
M*7Z.`TI"(`H5N,KLQ^GU?!?_``0'^%=QH/[.?B3QI=QV\4WC#4U@`@@,*/\`
M9%,4A`,:%E$[3(IY7$>5"Y;/WI0!_/!_P7*^(>B?"3_@X?\`"?BK7S#'H7A4
M^!]>U&Z&Z<VD=G?SW#GR@WS2&*-]L>UMP(P,D5^B^I?\',W[)MQ;/`/%'BYO
M/B4,5\)WW[CS!\N_=&``<@`YP2".U?GO_P`%K?#>C>,/^#D3X=Z-JUC9ZCI.
MLR^!;#4K6:/S8KB.?5)(I4D7Y5`:'@^82,!<D#!3]:M2_P""*?[)?V"Z,?[.
MWPC1G1V'_%/6ZJ"0>V``,GV`PO\`=&`#\I?^#1BR>T_;/^+2KN`B\+)&X1^%
M7[8CH"I`X&\@$DL-J@?*&`^I_P!HG_@X.^(WQ`_;(U?X+?LH_!>T^+>L>%KF
M>#4M4OK_`!!>&%FBF^SHKQ(D23@I]HEF"L8Y%"#`:OE'_@TKL96_:]^+,,#%
M;J'P2HLG=&\JT*WY0(RM^\(#,6"D\*V#D[=OS[_P1,^`WQC^)?Q[^('@;X:?
M'>W_`&=_'-A8(NK)=V<=Y=ZZUM+<13Q%<KY;VT@/F*,X,@9CDHU`'ZH?L$_\
M%YO&GC?]M(?L]_M,?"RW^#?Q#U"5;?2;A9FCM+NY>/?#;,CO*/WX600S),\<
MKHT0^?9YE?\`X*(_\'!VN?!+]NNR_9M^`GPTL/BK\3?M$5G>FYU(1QQWCPF?
M[)%`I4NRQ;3),\L:1$X((61D^2_C1_P3S\5O_P`%)/A0GQ@_;<^'?BKXS6VL
M:&VCZ>WA*4:K-#%J:W%M;K)$S*@W?:BA<@Y+G.T,5]0^,/\`P5C_`&B/VQO^
M"N6K_L[_`+/%_P##_P"%MEX>U[4M"?7]:TJ*XO[R6QB(O;IEN8V+8:-XXHX8
MSNX+N4RR`'2>,/\`@X2_:%_8L^.GA?PW^T]^SGHW@;2_$<8G#:7K*SW9MPX6
M6X@:&6Y@E\H99H6DC?'<<9]I_P""TO\`P6L\5_\`!+_XU?"[P]X<\(^&/%.D
M^-[">_U"XOKN1)[9([F"+]RJ.`Y9)7('.2OH#G\E?^"\_P"SU\6?V=/C'X`T
M_P"-WQV;XY^,KKP[?7L+-I\5A;>'K+S5B6-;?S?WBS.V6?;&Q^SC=(P"^7],
M?\';5@=0_:._9YCN()GM;KP[?VTV'C%T%>\LE<;G*]C@[@1\Q.%(+``^OOV$
MO^"Y'Q(_;\_:@U[1O#/P,U+2OA6NC:M?>'?$M[%>_P#$VN+18C;Q/*T*0J\X
ME5_*0N44_?<AL?E5XG_:U^.'B3_@N+H/Q6U?X'7\'QU@N+0P_#H22F1IHM+>
M)8E?EDWP3"4M]U$C^8\R;/Z;_!W@_3/A]X4T[0]%LH--TC2+=+2SM85VQV\2
M*%50/0`?6OPY^/%U_9W_``=Z^%VNKBR6.34=)7][>*HCW:#.L4>QU!,C,X(V
M,^W=&,IYFT@'[*_LF_$CQ=\7_P!F[P;XG\>^%)?`WC+6]-2ZU?0),[M)G.=T
M)R23MXY/7VZ5Z'110`4444`%%%%`!1110!X1^W]'O\$?#@X4[/BAX4/(R1_Q
M-K<<>AY_+->[UX5^WU_R(WP[_P"RG>$__3O;U[K0!YC^VN-W[&GQ;&U7SX+U
MCY67<I_T&;@CN*_C'TVZ2PL;<M/)%'*L28>1!`%==LF9,DR##H2!N+<X)PN/
M[0/VPP6_9'^*8#,A/A#5L,K!67_0IN03P#[FOXP/#A>S\/P3-`L'VNW;:C/O
MDEQ`"5/\38W$'/4DCY5+E0#Z=_X)<?\`!06^_P""6_[4=Y\2].\+6WB^>;PW
M<>'I+*_O1I*O#+/;S"5YS&X`C^S,5&W[KXW;0`/T8/\`P=^>,6.W_A0OAJ"7
M=LV2>++K.=Z)S_H(QR_;<<C!V94M^-_@?P_J_C#73:>&M#UG7]3^:1;>PTVY
MNI5@!"F5;6)-Q4D(ORKL7/H5QTVG?!#XA(6@_P"%8_$:=F!#A?"^H?+`5R'S
M)"0?G=!@C:H?`6-=]`'WY_P42_X./]=_;]_9!\8?"G5/@_X?\.Z1XMAM0=3M
MO$\M^UH\-S!<!L&UC`):+(&1TXWCEORUMK!+EX(9OLA@0LET&;=%=_Q;&.?E
M.,JI&`6'WN6KM?%_PR\6>"].;5-1\&^,]$TRT5&>_P!1\-ZA;1P('>)6\R5%
M14+-&IW.-S[``2=HY68P/=21F`SHLA$0BC66.)5(V%1N8'Y\KAL95@2&XD(!
M^W__``9GW0O-/_:+D20RQ23>'7!,F2N1JFX;=S`'S/,!QA<KA25`"_1?_!V5
M;K/_`,$H1N2201^.-%?8B,Y?#R\87YCGH`O))`!&<CYW_P"#-R[@F/[2,89S
M=(_A=I"TBN73R=256RORMEDD^8=<9R1BOHO_`(.QE0_\$FI]WD@_\)EHX5I%
MSLR\H)'!YP3SV!)[8H`_FN,#Z5"S6T1>)D\U9)5BB@0Y\X@ABJ@$[20Q9>C`
M*IWU^S'_``0)_P""RGP*_P""='[#]]X!^)NI>(M,\1WGBV^U=(],\-WE_$]M
M+!;*LI:)&&,QNN,DJ$&<9`K\;6LC)<1%$?RKF41L%DDW@A@'WJ74#B39M.T?
M(O8+Y?N_[+W_``3?^/\`^V/X$F\6_#+X2ZYXOT6+4KG3SJ5G>V-O';W$<27$
MD>)IT9L+-!C*H'8NN=V[`!^]?B;_`(.FOV3-#TAKFSU?X@:U,\;R6UK:^$KJ
M"6]VXR(S<B%#P6)+,`JHS,5&"?PM_P""L_[?=S_P4R_;.U/XFMIE]X1TF/2K
M?1='M/,BDN+*QMO.D+2R@#=*9YI&V+D8F*$OC!Z27_@A]^V$53=^S_XOV%`7
MVW^GNQ!(Y!,^X894(!+D<'8-F#\O?%+X<>)?A'XSN-#\;>$O$O@KQ!"D-S+H
M_B#2KO3[JW!(9)/*F175"%8!\;-K;CN!9%`/=/\`@DU_P3/\2?\`!3K]IRR\
M%6ECJS>`].OD;QQKL<`BAT>V"R/Y3R@']_,8G1(4V%6DRP98RR_UVZ9IL&C:
M;;V=K&(K:TB6&)`20B*`%'//``K^5+_@E7_P6A^*/_!-#QAI&F0:C>>*OA%%
M?G^U_"5S$03`Y<22V,CJHAN?,)<*QV2DJA=0%8?U!_L^_'?PS^T]\$/"OQ"\
M':C%JGAGQAIL.J:?<(>3'(H.QUZI(ARCHV&1U96`*D``_F\_X.C)5TS_`(*_
M^)I);B:TB;PIH$S22S>0I4BXA.Q@"`F&923A@7?'0,OYQZT?)\/ZA(US-F>$
MC"*4G(4>9YS':,+M$+'CGJH)#*?TF_X.BX9H/^"O/B&=_,15\'Z&RE$,)\C_
M`$H%O,XR0X8#D*3C./+R?SL-O]O&;OI*!&P24N`09(W!8?>(8_*P8-AD"[]W
MF$`_M8^#./\`A3_A3'E8_L>SQY?W/]0GW?;TK4\7^)=+\'>%M1U76[JVL=(T
M^W>>\GN"!%%$H)8MGMBOY4M)_P""X7[6>AZ9$EM\>_%BQ6P^SP!+#3;BW<",
MY42?9V7Y5?KZA3D;0*Y#X^_\%$?CQ^U5X5N-%^)?Q?\`%/BW0%CW-I]U<MI=
MK.-JES-#:Q1K*/DWJ)4*8QM!=?F`/$_%<D.J^.=?UBTBE_L_5-4O]1M);C<F
MU+B6>6)%D558?(ZN^Y0,%AC"L1]#_P#!&7P%/X\_X*H?L_P:6#>W-MXQCOVM
M'8P&VCMHYKJY(C(R!&L#-]\Y./E.YF7YK?246WDM[.Q=66,K<%HR\<:KDN0"
M`BX;<K9*9VX^8`!OV$_X-6?^">NL>*_C'??M(>(K*]A\.:#9W.C>$Y[R-HVU
M>\EW13WD*DD>3%`TL`*X4M,Z@?NB6`/IS_@[EO)--_X)?:%=*"T5I\0--GD0
MA=D@2TOF"ON(&PD`$'KD<BOYT'G>]<3F\NIXK5,&ZF@0DD>9E6W<MDJZ$-P6
M+;OX@?Z-/^#MR)Y/^"76BE)&AV?$+227",0H,-X.2"%7DCYG^4'&<<$?SI&W
MD\M9_)N7@@A6&4O;RR;&DVA$+)(GF#`R-K;<X!.]N`#^AC_@T5O([7_@G/XW
MMI+EGD_X63>LGFN/G4Z5HXRHPN!EAQC(WCA050?JG]IC,+2>8GEIG<VX87!(
M.3[$'/TK^*ZQ\0SVNG-';ZA?:?#>1@W)L[WRTN9=VYPJQG:6!PH+*=Z*.'$:
MO6C#K.KNX5=1U:VN_(1\)=S/%&H`!(VL^Y&"1#/7!`9ADN`#]B_^#MO]JCX?
M^.M$^%'P;T_4;36O&.E:\WBG5TL0MT='LOL=Q;)'+M)9))WG5E088K"S97*$
M_B9;W\-M:0&Y>2X6WB>7RRZ$LJK'G,>`&+?,=S$[U7(W*X+W;F"*"U9[2&S@
M>0Y@S;D2,VUF+E>!(<JP9]K$,0&QG#?;O_!!_P#X)^?"3]M_]JRTM_B;\1M+
ML(M"\RXL_`*+-;W?BQXG4A'N9$\J:%49':*"5Y&5R,(H=B`?M=_P;U?`R\^`
MG_!(OX1V.HV\UKJ/B"TN/$DT4C,2J7US+<0<-RI-N\)*Y(#%L$C!K[/NKJ*Q
MMI)II(X885+R2.P544#)))X``[TMO;QVL"11(D<4:A$1!A5`X``'0"L'XM_#
MBV^,/PN\1>$[V]U33;+Q+IL^F7%UILX@O+>.:-HV:*0@['`8X;!P>U`'X?\`
MQH_;M^*/_!>CX\Z]X)\#?%?1/V=?V9="#6VJ:WJE_':R^*+>9O+C$J,\,LK7
M`61H[9)(XO)8F5V<"(_:W_!.;_@G3^Q=_P`$Y1I=_P"'/&/P_P#&'C[28]D7
MBGQ#X@TZZU&T,B`'[*BLL=J&6;:/*4.5F(+MO.[\VOV[/V1_^"=7["GQJ_X5
MR)_VA?B9XUT.,P7.D>&=;LKR+3)&7"VDKRQJ7E"QD&*(2R(O#*`,+YW^SS\.
M_P#@G1XX^)&G>'O'VC?M._!K4]1=5%UXDN[%]/D4R+'$9PMMYR!G&TNUN(TV
MC]X!D@`_>7_@HE\0O#OQ1_X)4_M$ZKX=\0:+KND3?#3Q/`-0TZ^2ZM@RZ7<J
MX\V(L!M/WL'*X/3%6/%/[$'PD_;K_9K^%]I\5O!6C>.['0](L[W34O?-5;:5
M[6(-(@1U()`'4FO+/B-^P]X"_P""??\`P1$^._PV\`7>L2^%(/A]XMU%+J_N
MHYKEVN=.NI9'\R*-%QEOEVKP`,9Q7U%^S)/)=?LV_#V6:)H)I/#6FL\;)L,;
M&UC)4K@8P>,8&*`/RV_X+S_\$G?V</V2/^"8_P`0/B+\/OA/X:\)^,=&O]&-
MKJ]H\XFMEEU2UMY>6E`"F":53R,`YXP,?@U>621SD,'BF*;E`MY'N(SY@$@<
M%6;8!&GS)C(/`#HP7^G'_@YHV'_@C!\55='<O>Z`BA0K<G7+`=&&#WQT.<8.
M<5_,A;-_H<0C2W%I&-H=E61)5.\/L25&*IYFW>>O//);:`?U(?\`!O`^?^"/
M/P>4,72.'4@C^64$@.J7AW`$YQDGL,=,<5>_X*1?\$1/A/\`\%1/B?X>\6>/
M]>^(6C:GX:TMM(ME\.ZA:6D4L+3^=F3S;:5BP;."&``)P,DFJ'_!NX&3_@CK
M\'5(?:L6J[6DG::63_B;WNYG8@'<6W9SSW."2H^U:`/S6^!G_!K5\`O@%\=_
M!_Q`TWQO\:=5U/P7JT&L6MEJNKZ;<6%W-%()`LZ"P5V4E0&VNK%0!NP!C[@_
M:]_:F\+?L5?LW>+?B=XQNEMM#\)V#W;1[L2WTV,0VL0YS++(4C08^\X[9K4_
M:(_:%\)?LK?!K7O'OCC5H=%\->';8W%U<.-S-V6.-!R\KL0J(O+,P`ZU_,A_
MP6#_`."N'BG_`(*B?&%9Y([CP_\`"#P?.]QX8\.S8\V8J.=1O4`;S9I%==L9
M62.*-2$5FDD9P#X\CN//9KFZR=0GFDE$4T2DI,3M,9)`7='\N55Q^1K]YO\`
M@T`@33?V=OC991Y6*W\7VI1!D)&OV&-0`"JD85!G`"YZ#N?PZ\#^!]<^+OC[
M0O"/AW2KOQ)XMURY33-*TRT@::[NKF51M5=P&Z)$5R[G@*58LAB8C^I3_@C+
M_P`$XX_^":/[&5AX3OY(+GQMXDNW\0>*[B!R\/V^5$001$]8X(8XH0W5S&SG
MER``?65%%%`!4=W:17]K+!/%'/!.ACDCD4,DBD8*D'@@CC!J2B@#^?C]O[]D
MC4?V%OVFO$_AMX0?".KF34?`]P\AF,5FZ(&69BP.86\RS_>^:S)*K/\`+/\`
MN_%5\27%YHJQ2W45L\]C(DL:W#[(D:20;@94\N25T$:@QI((VA`?=RU?T"?M
MZ?L1>'OVZO@A-X:U1UTW7-/D-[X?UI%8RZ1=@$;L*REXG4E)(]P#(W!#*CK^
M#GQ3^%7C#]GKXR:IX/\`&'AX:/XGTJ:&:RB,26_V^2-BOG(06^UVSKPFU2XP
M@5RX98P#)U*2YT35;FZFAL[:%I8$,DP>-E>3;$TA:=6$D<D;&(@)N",FPA=P
MKZ%_X)'2ZMX9_P""A?PQ@`;RA=7L,B2HJQ6L4EA-\\9"KO>0/$&5=VW=&Q(4
M!G^<K;55U9K+4;4R"&TF;+8P?)DQ,0F",[]KJ6X#;50'",1[#_P3[U*/P3_P
M4<^$>I0#2$M_[:M[$QQ11O<1--%/`(PR>2I94G(:,*^P;<>:57`!]&_\'!'B
M62W_`&S/"%FDZPQVO@I)I26#@>;>W2(WED\G?&(QT+><0FYPH'PIKT5Y_93Q
M7(L5!<Z>AFE\D23!$8/)-'')%UD0O&,%#*TH5LKC[`_X+N>))-9_X*%PZ?;K
M%))HWABU'G31AHK=V:60*0Q*."3'D%=H,D;/D("OQQIFC"V2ZC73T$5M#%]E
M6:6.XBMXWE,N%C24%@ID$>0Y5L_>'[PT`7H[07%X+>"+S8[9$CM[80H;FW8'
M=&WW/*5I%C53`CNQ+XC<E5SU/[//P2\1_M#?&+P[X%\.6>F/K>O7,A602NUM
M828\R>\F38'"('D3?&X9A$%()9P.8M=-UOQ;/;:9I]E+<Z]=W"V_]F6\(FGO
M%DD)MUBA@S&1),KAPZD,URY?RL;U_:7_`()1?\$X(?V+_`=UXB\1PPS?$/Q3
M$OVO[DBZ+;G#?8XW`^9BV&EDR?,9$Y(C2@#Z2^!GP=T;]G[X/^'/!?A^UM[3
M2?#=C'90K#$(A*5'SRL!U>1RTCL22SNS$DDD]7110!\:?M4_\$1_AI^UI^W/
MX8^/^M>)_'VD^,/"DVD7%M:Z;>VXL)FTVZ-Q"'26%VV'<ZLB,H.\DY)K[)GB
M\Z%TW,F]2NY3AESW'O7P[_P<"?M]ZC^P;^PJ]QX7UJ;0O'OCK5[;0M`O(!NE
ML3N\ZXN@-CY6.&-@1M.3(B]6%>2?\&Y?_!0CXE_M%I\6?A5\<M8UW4/BCX"U
M5;Z./7K6.SU.&R=4AEMY(55<-!.F6.,@74>0`5+`'MG_``34_P""'?PX_P""
M7GQA\3^,?!7B[Q]KESXGTXZ9+9:W/9O:VT7VCSP8Q#;QL"&R`-VW!Y4L`PXK
M_@HM_P`&WGP._P""@7Q3N_':WFO?#GQGK4RRZW?:$L$T&M$#_626\Z.BS[EC
M)ECVLP3#;LY'T#^US_P5B_9V_83\2PZ)\5/BIX?\,:[.J.-*2.XU#4$5U+(S
MV]K'+*BL%)#,H!['D5V_P,_;8^$7[2_PKO/&_@3XC^#_`!+X4TR(3:AJ-IJ<
M7E:6I3S/])#$-;G9\Q64*0.2*`/F#_@FA_P;Z_!S_@FU\6+CXAV5_KOCWX@X
MFCL-:UN.WA&CI.A6X-O#;QI&)90S*TK!GV$("JY#<M^W3_P;@?#G]L#]JV;X
MR:!\0O'GPJ\8ZI<QWNJMH)A>&[NHUC5+J+<HD@GVQ@%T?G@@*=Q;USPG_P`%
M[?V._&WQ/_X0_3_V@/`;:R9&B5IYIK:PD8#.$O)8UMF)SA=LIW'A<GBO?OV@
M?VJ/AM^RGX`'BGXD^.?"_@GP^[;(KW5]1CMH[E]NX)%N.97(!(1`S$#@4`?G
M)XQ_X--/A/X_\.:=+K/QA^->J>-UD=M7\4W^J0WUWK492)%A=)XW18T$9VCE
MOWC[F92%'N__``4=_P""'GA;_@I1XT^&&O>)OB%XM\.:A\-=,;3%DTBWM@=4
M5Y8)&>3S$;:0T&Y0`0&8'!Q@^V_LL?\`!3/X"?MK:I-I_P`,?BCX8\3:O`7#
M:6)7L]295&6=;6X6.=HP/XU0K[UL_M3?MZ?!O]B>QLIOBI\1?#/@R34E+V=I
M>W.Z]O$#!6DBMHPTTB*2`SJA5<C<1F@#UROSU_X*B_\`!O%\/_\`@I1\<C\2
M5\:^(O`7BR^LK;3]6^S6<.H:?J\=ON$3R02;6$@1O+.)-A10#&3EC]/^#_VS
M/AW^UC^SKXQ\2?![XI^#M4_LO2;@MJ]M>12KX<N#;N\4MY$ZLT&S'F%9H_NH
M<J1D5Y#_`,$K/VBO%4O['OB/Q3\<OVBO@E\7VT3691-XV\):I9Q:'I]KY4`%
MO<2I#;PQR+(78D_PS1@GID`]W_8E_9AMOV+OV3?`/PJM-8N?$%OX%TB+2EU*
MXA$,M\4R3(4!(7)).,G'J>M>I5\P?#C_`(+3_LH?%KXAMX5T#X^?#>\UH/Y2
M1R:HMO#.YE$2I%/*%BE9I&55".Q?<NW.17SK_P`%0_\`@MM<?L@_M]_`OX8>
M"_%7PMN]!UWQ%#I?Q+74)A/?>&89;VQA5G9;A%M2(;B27$J'*KD<4`?I317P
M;\>/VJ_'?Q`_;T^!=W\(_P!I;]G?3O@IXLM[.2_\-7^N6LFM^,LZA<132Z:1
M;2F566-($V3H&E5U!5@"_P!.?M)?MS_![]C_`.PK\3?B1X1\%W&IG_0[74M0
M2.[NAG!=(`3(R`\%@NT9&2,T`>K45PWP<_:;^'G[0OPR?QGX&\:>&O%?A:%6
M:;4M,OX[B"U*QK(R2E3F)U1E9D<!E!&0*X?QM_P4R_9X^'G@:P\3:K\;/AA%
MX?U2=[:SU"#Q':W4%S(C*LBHT3L&V%E#8X7<,XS0![C16/X!^(.A?%3P?8>(
M?#.L:;K^A:I'YMI?Z?<I<6URH)4E74D'#`@\\$$'D&MB@#PK]OT,O@#X?.L;
MR!/B=X2W;1DJ#K-JN?H"PS[5[K7A7[?RL?A[X`9024^)WA$Y`S@'6[0'U[''
M0]>WWA[K0!YO^V._E_LB?%1O[O@_5S]XK_RY3=QR/J.:_C"T,B'3;>.5X&9+
M96GEA`F1LRB-G<L@95WANH(7YP%<JHK^S_\`;!S_`,,D_%+:)&;_`(1'5L!#
MAB?L4O0]C7\9^D0?8_"UJJAF@C@C#JIC15_=%5)'S["Z@Q$9._9RW6@#]&_^
M#5![:/\`X*X2[[:)KE_`6K!7?=&4)GL&\U`6;=O`<`YP5!()P57^ENOYJ_\`
M@U8VI_P5G8B2-=_@351LD*F3/GV88$`G:YV@L<\E23SG']*E`'Q!_P`'';/'
M_P`$8OC5(C^4(K33V>0,%*+_`&E:`]?4':?9CTZC^5J.)-=C@,]N=0MK@;HW
M@D6>1'S&3&4V+E&B`P'!++'#@JF%7^JG_@XSA6X_X(R_&M&6,EK33U3>NY0Y
MU.T"'J/XB.X_'[I_EE%N[WT+W5M#/*1NEDVHLT@=EPTAEQ\_W!M7>"201R^X
M`_;7_@S7OI;J?]I!7:3:!X7E*R,696:/5,J<\@J5*X)/`7ITKZ4_X.OY4@_X
M)*WKR+"T2>+]'9S*K,$42.2V`R\C&>H^H^\/FK_@S>BFL]:_:5@N)4>58_"S
M;!:S0M&&_MAP&\Q%Z;MH`S@)U.0Q^G/^#J[RQ_P2EF:788T\9Z*[*S*`X$SD
MCYB,Y&>,'U(VAB`#^:;5;$)&)9#=F,``QEBI,T@EE17W#Y`-R(&X.-[%<C-?
MT7_\&A^3_P`$SO%Q*D,?B1J6\E@_F-]AT[+A@H!!&,<MTZC[B?SL-9I*9!'<
M)"[VQ\R6*Y9!-*%9XL[F"D%QO)WX?(!*A3L^J?V)?^"MGQ\_X)^?"B\\'_#+
MQ1I.D>#KB^DUJ2"?P^FJ3/++!`AD6XD5W=2MO\N[H%8$+M"T`?UFU^-__!X9
M\-/",_[/OP=\8-!:Q_$6V\7-I.GRI`&N;K36LKJ:XC8@AFBCECMWQG`+YQ\Q
M-?$9_P"#EG]L&1@__";>$VC29S(UIX4M9XMN,</C)1<H20"Q+J,8)9?E/]KO
M]LOXG?MX?$:T\3?%?Q=?>*-2M%CM[2'[-]FMM.5AN9(88X]B@/\`?&TL<;@S
M`I0!Y#;CRK@^;J`BM=AN8PC+MF5A'E\EEPJQDC<S>7B3[H5N?Z5/^#5WQ#?Z
MM_P2OM;&^-\Z:)XIU.SMFN7+%8\QR",!F)3:9#\N%5<X`R"!_-G<7D8DF\E[
M]HO-_=+$7#S'YV8HJC<'\PE!Y:JR-*3MVX-?U=_\$0_V,=4_83_X)M^`/!?B
M"*>T\47T<OB#6[*5LG3+N]<SFTP,@&!&2)MI*EXW*\$"@#\1?^#I"7/_``6`
MUQ`EN=O@W19FBCD#^?L%X1)*I(*E#W3@#RV)W'8_YX7]W<6FG3JDEW<;8=K1
ML99I5@4;5=?F1O*!4HJE3MV@'+@BOT;_`.#IBX>;_@K/K$>^5$3P=H?S($RF
MTWQRN%.6Q(<%\$$@CY1N3\V_$L<=M8:@9,!T1MT"*K1N?++B++?.N\Y(3&-S
M$$2;5-`'[.^"_P#@T6\4^.?"^EZ]#^T)X8A&LVUO>QRCP--.R(T8<-\VH8<L
M3N;(P6<D8`"G2C_X,ZO%5U>RM=_M`^%9%,OF+(W@*YE9MTB%LJ=2&,(./F.=
MH!QDO7[4?L_2>=\!O!+^4T._0+`^6PP8_P#1X_E([8KKJ`/RJ_95_P"#3CX*
M_"?Q):ZO\4/%7B/XP26>'CTJXMXM)TAGR"6EBA)EF'&-KR["&;<K%F)_4?PS
MX9TWP7X=L='T;3['2=)TN!+6SLK*!(+:TA10J1QQH`J(J@`*H````J]10!^8
M'_!VW:M>_P#!+/2XL1/'+X^TJ.2-\CS0\-V@48R?O,I.%<D`@*2:_G/M+&1)
MOM$4>I2+;H/,8P>8@^;?Y9&#M9E5F'S,VY6Z@[V_HT_X.U&;_AUCIZ*-_G>/
M-)C\OD>;F.ZPN[D+SCYBK`>G<?SE#3X;:U0JP$KL@$H3<@P0&A!7=\Y!C^49
M`4*!P6-`'ZF?\$+O^"'7PG_X*>_LK>,/'7C'Q=\2]%UKP]XYN_#MI_PCNI65
MO;BT2RTZZ0LDEK*&ES<')SCY$!7"[:^RT_X-"_V=X@2OQ`^-C.(XXXV?5-,8
MQ^6FQ''^@`%\=<Y4X`V@9!D_X-%21_P3_P#B>FYW6/XJ7JJS,2<?V-HV`,@'
M&W;SW.37ZJT`?RA?\%;_`/@E=XC_`."3OQIT+PY<ZT/%_@[Q9;/+X<UN:-8I
M[IHN)K6>'<=LBEXSB+Y9$?/RN`*^9O!_B36/`'C'2O$'AK5;_0]?\.W::MI-
M]:,R7,%Q$QF1PQ1MQ1UQG&`1)R=N1_0!_P`'<_@*/6?^"?\`X#\2PPHVI>&/
MB!:".1VC55AN+*\CD5B_`4NL!)`R-G898?SXV\4#7D,MM)#-`09D8VYZ'<%5
M"J;?,(#C=M/,<A(R%90#^Q+]B/\`:.@_:\_9%^'/Q,MX7MAXTT"UU.:!DVF"
M9XQYT>,G&V0.OX4G[</QWN/V7OV-?BI\1[2!KF[\#>%-2UR"-=N7DM[:25?O
M?*?F4<'K7S/_`,&UEZU[_P`$8_A)NG$_D3:Y;I\SEHHX];OTBC*O\Z;8U0!&
M^ZH4#"@*/<?^"IW@/5OBA_P32^/WAW0;(ZEK6L_#[7+6QM%7<]U,UA,$C0=W
M8X"_[1'(ZT`?G;_P:;_LFZ3K7P9\??'WQ7I::O\`$'Q)XKO-.M=7U&W2:=(E
M2*:YN(97&]7GN)I/-9=H9H=N-J*3]0?\'$7['WA7]I/_`()F_$7Q/J>FVK>*
M?A3HMWXJT/4O(5YX/LT327%N20289X%DC=#\IW`D';7E/_!I7\4=.\:?\$R-
M2T*UF@-WX3\8W\4T/VG?+Y5RD-W%+L)WK$PF9%9L;S#(0`!@?77_``5P^(D/
MPK_X)@_'S6I9;6)X?`VJV]L+A=Z37$]L\$$0&#EY)9(T48/S.O!H`^'O^"=/
M[1.H?M$?\&P'Q:AUBZ.J:EX"\">+_"$L@+E6BMM+F>VC4EF8JMK/`@P>BC``
MP!^F/[,EK]A_9M^'L&PQ>3X:TU-AC$93%K&,;02%QZ`G'K7Y*?\`!&KP)?>%
M_P#@V9_:/O;I5AM?$^F>,]0L6#!D:--"CM)&#\JR_:+6?#<CZXK]:/V6]G_#
M,OPZ\O;Y?_",:9MVL6&/LD6,$JN1[[5^@Z4`?)'_``<QW'V7_@BY\67\R)`E
MWX?<K(2J2A=>T]BI((`&`2<\8!'&0P_F&.Z&R:21(I[J,`PQOC?&<==V,%SD
MCYAWCZ!=C?U`_P#!RC`\_P#P1E^+.PN#'<Z#(0J;]P&NZ>2-O?VY!!P0=P`/
M\PEP(&CLV\F*\C:(D1C)$@?`!RH&/ODXP0ZKST&P`_J$_P"#<:W6R_X(Z_">
MW`E4P2:PA5P0%_XG%Z00&56&00QR`<L?K7V=XU\9:9\.O!NK>(=;O(M.T;0K
M*;4;^[ESLM;>%&DDD;&3A45B<#M7QE_P;C"=?^".?PF6=@^R3651@[/O`UF^
M#-N;YF)?><MR?UKPS_@Z\_:E?X;_`+&WA;X4Z?>-;:A\5M8+ZB$^<OI5BHFF
M0Q@@NLD[VB$?=(9@2"RF@#\H_P#@L'_P5A\2_P#!3;X^G4[>YDT_X5>%[F2+
MPAHKRO;QSD.RK>W2EE;SIA&Y&4)B4!`-VXGYG^$OPB\2?';XHZ5X"\#:+JOB
MSQ?XAO772].TV%!YKE2\C+T6+8,2/*[*$#;G*$%3FVACW;HF/GNR&*3R@_R!
M&6-WV_QMN3+*Z`>4>4W"0?=7_!&?_@IG\,/^"6^D^(-;U#X1>(OB!\2->G-G
M/XC35X(Q:V2/M2VMED7.69@TA4!FXW<1@``_7G_@BE_P1,\-?\$SOA]!XH\1
MQ:?K_P`:O$%@L6JZJL8:'0HG`9M.LF//EJV%>7AIBBDA5"HOWM7Y!?\`$7EX
M`W*#\$_B`1*ZB%H]2LY1(IR,G83R&`!`SC/)!&*^S_\`@E;_`,%7?#O_``54
M\(^,=8\.^#_$/A.'P;?6^GSKJD\$OVF26-G.PQ,0`NW!#8/(.`",@'U=1110
M`4444`%>$_MY_L#>%/V[?A@VEZN\VD>(].C<Z-K=K@36CG!,,H(Q-:RX"RPG
M[Z%MK(^UU]VHH`_G+_:H_9R\??L:_$F?PEXUT,-=W``L[JV5O[+U<-&3-<VL
M[(/-E$9;<GEAEVL"IPK'!_9V\8Z=\'OVD_!_BZX*E_#/BNWU6]MK`<SK#>>9
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M<^'_`/8'@;2WB,P`O-3O-DFH:AAW91+*JJ"%+MM4`*H.`!0!XM_P2_\`^"5.
MG_L5Z7_PE'BFXMM=^(NI>;*6C&^T\/K,3NM[9B`6(C\N$RX4LD*+@`'/V/11
M0`4444`?@G_P6O\`C9KW[7'_``6X\%^!/#?P_P#$GQL\(_L]6MGJNM>"M$@:
M[&JSB:.[O?,01S1^20VFVK^8@SNFC!RP!Y"/]M#Q5^R__P`%Y/!?[0?Q$^#7
MC?X%:/\`%L#0_$.E:K;DB_C>VMK&:YAD\N(.L<Z:;<2IM+_NW;+@*3^R_P"R
M_P#\$ROAA^R1^T9\1_BMX7BUZY\;?%.:2;7+[5-1-W_K+A[AUA!`\I&D?)4<
M82,?PBI?^"A'_!-7X9_\%,?A[H'ASXDQ:VMKX:U)M3L;K1[T65XC/;RP21>;
MM8^4Z2Y91C+1QG/RT`?FE\=/V=_B1IO_``6V^,/Q;_9+\:_!/XE_$]+)++QC
M\/O&5K-;7^DK);6=J54E8TGB,<"R!DN(6`9UW2*[!O/?V-/%/P5\<?`']M;X
M8>,/A9H_[)OCNY\.R1>.O$%GJVH:EX?@,U[)"N+1Y9(K5%NYR$C@RCQ/A25C
MQ7Z,?M'?\$%?@E^TM\1K/QMJ.J?$SPSX]BTF+1K[Q-X7\2OH^H:W%$D<:/=>
M4@B>79$BEUC4L%4-D(FWI?V5?^"*/[/W[(_P;^(7@K0_"]]KUE\5[-].\77_
M`(AU"2_U#7+9ED4122_+L4"5R#&$.X[R2X#4`?D!\2?"/QH_9;_X)G>&=%^+
M?P4^!?[0G[+-A<+JNA^*=`UF\T_4;=K^YW`BZB>&Z'F%WB;_`$<AS.JR3NN:
M]`_;2UKPE^UA_P`%E/V%_"OBT:E9?`O4_`&B:GHNBZU>R7Q:WNDN&B%T97;S
M&N;B#3[261V8R*BEBQ.:^TA_P:X_LW^3%I;Z_P#&Z7P5!>_;(O!\GCF=M"B_
M?--Y:Q%?,"[W<[A)Y@+LP<.=U?1O[:O_``2=^"?[>?P,\-^`/&WAN>UTKP5%
M'!X;NM'NC9WF@Q(B1^5"V&5HS'&BF.5'0[5;;O1&4`_,O_@N=^S[\._V0O\`
M@I1^R/K/P/\`"WAOP/\`$;6-=5;_`$GPKI,.G_;K(7UE"EP\<"`&0^;-"K8#
ME7?!^7<FM^SS\+_!'[9'_!S[^T#IWQLL]$\<MX(T]XO"&A^([5+NT010Z>8@
MD,O[J3RHKB[EC3RR099ILEEWC[6_9(_X(&?`O]D?]H"U^*,%UX_^(/C?30!I
MVH^-M<&JMIS*KI&\:B-%+QQNR1LX8QJ<(5R<]'^WU_P1>^#_`/P4'^)>A^/-
M>F\7^"/B-X=B\BT\5^#M373-3>,*ZI'*S(Z2!1(X4E=ZAV4,%)%`'RQI7[,7
M[)O[+?[=W[1&F?"+QYKV@?%"_P#AOK%OK'PMTJR,'AO3X&L8KEVBD^R".+#.
MDHC6YVQR7$H55&Z,?"7[%/Q/^$7PP_X-K_$<'QETKQ3XJT;5?B7%%HFA>']4
M&G7FMZE%I]O<PQO,58+;J(&E9I$;:$3]VQ$>_P#93]BO_@BU\&_V$?`'CO2?
M![^+M1UKXCZ?+I>M^*-:U)+K7);>2,H5298DCCY8R$K&"\F'?>0"."\,?\&[
M'P'\._L#ZO\`L[3:K\1M6\&ZGXB7Q3!J-YJ=K_:^E7R0);QM;R1VR0A5C4C;
M)"X;S'W;MU`'Y1_\%JOA3\1_#7_!.KX06_B']E;X4?L_^#=&G_LG1WTWQ#%K
M'BEW.FW3)#*\%O"BK-AY96<N3)\SX<G=[;_P6)^`7@#5_P!N?]@/56\(^$YM
M0^,&KZ4OCBZ72;82^+8YKO1HG:]/E[9U*,X(<8VLWW068?6OCC_@UP^#/Q5\
M$PZ'XP^,7[4'C&#3FC&CS:YX[COGT")5*-!:)):F*..1-BMF-CB&/:5()/M_
M[>/_``16^%7_``4,^&WPVT#QIK/C?3[[X6VHLM'UW2KNU34I8BD"N)S-;RPR
M,WV>-]WE`HX++MR00#\]O^"EGP;\,?L]_P#!P?\`L:^&?`OAW1?"/A?3=/T*
MWLM(T2UCM+:W5_$E[-(!"@"JA=W<[1DL[$XR34O_``3U^`O@G_@HU_P7:_;$
MNOC[H.F^.K[P5J]YI/AW1-<B$UDNGV^I3V<+?9Y"=X2"VMF7(*AKAW&/,%?:
MFC?\&_/PJT;XK?`OQBWCWXOZCJWP"CACT4W^KV4ZZMY6IW&I*;X_9`TA\VZD
M7$;1@(D0`!4EM;]M7_@A/\+/VP?VA4^+>F^+OBC\&_B:\`M[SQ#\/-=72+G4
ME"[0TV8W_>;0JF1-CLJ*K%@```?GG^S;X>L/V-/^"]W[6'P@^%EK%!\+-3\!
M:I?7FA0W+G3-,E72+*[.V*,A46&XNG@"`@JMT5&W9SB?\$'?^"=WP7_:@_X)
M/_&#QS\3O`]EXWUW09-0TS2;[5?-9]"MH-&MIUAM-LFV%TEE=R\2JY)4L[L.
M/U&_8'_X(Q?"K]@#P3XULM#O?%'BKQ+\1+::QU[Q1X@O$NM5NK>0R'RE;8$5
M<R,Q.TEW^9RV%`T_^">?_!*/P?\`\$YOV7/%?PI\,^*/%GB'1_%UU-=W-YK+
M6S74+2V4-HP3RHD3`2%2-RDYZDG)(!^>/_!MU^UYJ'[-_P#P1J\::HVE2>*M
M6L?B3J.EZ%IOVDVUF2GAZRU2XDDN%B<QVZI'?W+ND4KD9$:2NT:-^C7[`'_!
M12V_;2U#6=+GTK2["_TZV&I6%]I.I-?Z9KEE]HFMGEA>2.*59(IH625#&41G
M15ED(?;YE^RU_P`$'OA[^RG^Q'XB^"ND>,?&.HVNN:]+XCAUNZ-NEYI]S)IT
M>FLB+&BHT+VB/#(AYDCN)EW+N!7W;]DS]AW2/V6O$_B;Q`NM:AKVO^*3MF=H
MELK"QA,\UR\5M9QGRH1)=7-S.Y`RSS'G````W]OMO*^&W@67`9H_B9X/"I_$
M^[7;-#C@DX#%CCLI)(`)KW.N*^._P;C^./A/2M*EU&;3%TOQ'HWB$2Q1[S*V
MG:E;WPA(R!MD-N$).=H<D`D"NUH`Y3X\>![CXG?`[QGX:M!$;KQ#H5]ID(E<
MHA>:W>-=S`$@989.#CT-?SC:=_P:O_M>Z;8QQ?8_A1+)$H=6?Q3(Z>:2"S!3
M:?+QA>#DA`"23OK^F2B@#\9?^"&'_!#KX[?\$^OV]O\`A8?Q`T_P-;^&!X:U
M#1T_LS6FOKB&6XDMY%"JT*G:#"PW;AP<;>2U?LU110!\V?\`!7S]F;QA^V+_
M`,$YOB9\-O`,5A-XN\46MK!8)>7GV.%ME[;R2AI=K;<PI*.G.<<`YK\*Q_P;
M`_M=Z->6DMOX6^&UQ%9.52!/%:QK,@+##DP_==`JE%`&UADC&%_IGHH`_,'_
M`(-PO^"6'Q9_X)I2_&(_%#2="TM?&4.A1:6-.U*.\\S[(=3,V[8`$4?:X]JX
M`Y;'H/=/^"[W['?C_P#;G_8#O?`?PTT^UU/Q3+K^F:A%!<WZ641B@FW2$R,1
MC"\@`@DXYK[*HH`_F+N/^#:/]L73YI19>!O"8B2*,1>7XMM8\'&X\`@DHPZ,
M<.2#E5RAAN_^#9[]L,ZD96\!>&+G:3L+>,+6149V7<PRR'`)=]Q&\DOG.$4_
MT]44`?S$WG_!M9^V/J5_<W4W@/PP3).6E1O$VGO)=+N#8WEB2"1SO.[@8*X!
M'0?#'_@UB_:T^(-]#_;?_"MO`MM'.T5Q)J7B(W<KQ.!NDCCM+:1)``S#9(T>
M]DY*`C;_`$K44`?G3_P31_X-Q_AC^PGX^L_'GB[7)_BW\1--E2YTZ]O=/%CI
MFCW"]+FWL_,E_P!(':621RN,H(R6)_1:BB@#\1/^"]O_``2!_:1_;/\`^"@-
MUX^^%O@A/$OAA_#>EZ>D\GB2QL"9[:2XD:,1RS1N%!D7!)^](QS@#'Q;?_\`
M!N=^VA-8W$2?"D&9<Q02GQEI0"KA]KJ1>[@RL3@<85L`Y9VK^HVB@#FO@QX>
MNO"/P>\)Z5?0?9KW3-&L[2XAWJ_E21P(C+N7Y3@@C(X..*Z6BB@`HHHH`^%O
M^#AO]D7XD?ML_P#!/H>"?A7X5G\7>*F\36-\+.+4K:P:*"-)_,DWW%S;Q$?,
MJE69_P#69"$@,OXFWW_!O5^V@TIG?X%W<\CJRF3_`(2;PV7505**5;4&5@5^
M0Y5]NWY1D!V_J;HH`_/?_@W$_8R^*?[$G[(_Q!\/_%OPG-X0\0Z]X_N=;MK:
M>_M+V:XMWTW3HC*7MIYXPIFAF`4R%LAF(`89_0BBB@#Y(_X+A_LE>*_VTO\`
M@G)XO\&^!K"YU?Q?'?:9JVEZ?!<00-?O;7T,DD6^>2.-<PB7&YUY`YSBOP*M
MO^"`?[9<,D7F_`SQ,1&JR,IU_P`/RK&K_>CCQ?!E(&%&&P`J!E!!)_JLHH`_
M.C_@VZ_9V^-W[(O[+OCCX>_&;P'KGA`6_B<ZUX=GU#5[&^6XM+FU@22!4MIY
MO*9)[>65MQ&YKLG&=V?T5EB6>)D=5='!5E89#`]013J*`/QE\>?\$J_VI?\`
M@E)^V1XD^)7[&UOIGC'X=>+S+<7?@N_O(5CL%>5G%D;>::W62&%II'MY8YQ)
M&H*,C#=YV3^TA^S/_P`%$?\`@LQ?Z-\/OBOX1\+_``!^%,&IP7.K-97UO*&:
M,*WGD17EQ->M%(A>"(BWB+R*9&.Q73]L**`/G#XD?L;V/P:_X)4^./@E\,=)
MFO/LWPYU?P]HUIOC6XU2[FL)T#.YVIYT\[EF8[5WR$\#IZY^SEH-_P"%?V>O
M`>EZK;R6FJ:;X=T^UO('QNAF2VC5T.&89#`CAFZ=3UKLZ*`/D[_@N+^SSXS_
M`&K/^"7/Q/\``/P^T.?Q+XOUXZ3]@TR&X@MY+KR=7LIY0))V6)<112'+,,8X
M(.#7X$I_P0?_`&S(L%/@5XH@@G.Z6.'6M$0MNQ\N3J3$JH?HYR0@&Y&5BW]4
M]%`'R;_P1`_9Y\9?LK_\$T_`7@CQ]X?E\+^*M)N-4>\TV22WD>W$NI7,J9-N
M[Q99'5OD8CYOPKX@_P"#D[_@GY^T#^W%^T[\/;CX:_"K4/'/@WPMX2N(9;VU
MU+3;<I>W-TS30;+FYB<XCMK5MP7JX"D_.M?LC10!_*[=?\$'/VSM0L9HI?@9
MK\_V@PF9KGQ%HS--,"3YI/VPY!WD\JH1BWRC<U5F_P""#O[84UH%/P$\5'"*
M#<S:WH[R+O;!41F_?Y5SC`Q\NYL*37]5=%`'\I=S_P`$2_VO@(I!\`/%$4LD
M9$C1W6G,0&=T\E]LX#?NV*F3!^4L`#NP_P"M?_!L5^R)\4OV4?`7QF3XH_#_
M`%CP)?>(]:T^YL1J*H'O$2"57V[7;*H['&0/O]^@_4FB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
)HH`****`/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>oasis.jpg
<TEXT>
begin 644 oasis.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`"2`B4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_*X#]HS]
MI/PU^R[X-TW7/%!U#['J^LV>@VBV=OY\DMW=R>5`F,@`,Y"[B0!G)(&2._KA
M_CY\!/"_[1'A?2M(\70?:]*TC6['7X[=F4137%E,MQ$L@8$/'O0%E/4`T`>1
M^&_^"LGP$US3++5&^(UI;66JZ;;ZF@GL;D1Z?'+#=S1K<2K$8X)9([&[9(I'
MW2+;EH]ZLI.NW_!4?X`)I-Y?O\3M!BL].AEGNYI$G1;1(],AU5S(3&-A^Q3Q
MR@-@MED`,B.BT_B!_P`$W?AAXC^.%E\1]1DU*P_LV;1[Z]TM+B&'1[V71XKN
M/3II(_+!C\A;R;Y8GCC<;1(CA5`^??`O_!+K]BSP'X9_LBP\6Z!);V/@V^^'
MET\OC*VEGN+66XBNI9;AV8DWL3[0LGR[866$J80J4`?2T'_!2SX)3ZC?VO\`
MPFRQ2Z-I][JNKF;2;Z*/0K6S>>.XFOW:$+9*KV\J@W!CW$*%W;TW8GC'_@K;
M\`?`_A#4-9N_&\\J:3]I-]8VVA:C-J5@MLUHL[SVBP>?!&AOK/,DJ(@%Q&=V
M#FL+P;_P3<^"_P`4?"OBF9-?U3QWIGCSPC>>"M8N8]6@>WO].N[F6Y<1FU1(
MX2K2D)]GV1HJ@*BX(KE/B[_P2/\`@;X;\`R7/BCQ?XLT#33;WVEW^ISZM8VD
M,UG?/I[/:,C6XMX8A)I=BR?9XXW#1EMQ+R%@#VOXN_\`!0?X5_`SXO7W@KQ-
MXCN=,UW3K6PN[I)-(OI+6);W[;]E07$4#Q&XG-A<K'`7#RM&$0,[!3V_PC_:
M-\#?'R[U.+P5XETWQ.NCP65Q=W&G.9[:);RV6ZM@)E'ELSV[Q3;%8L(YH78!
M94+>=?$W_@GMX!^-OQ_M?B5JE]KTTSC1))]*M[B!=)U3^R)KRXTUI5\HRD13
M7T[X255DRJR!T&PY?[%'P<^%/[`'PFO/!NE_$/2-2GGN_P"T]0O=4U2TCN6"
MP16ENF%*[88+6T@MX@<[8[95W';0!]'T5RMW\=?!%A&[S^,O"L*1;M[2:M;J
M$VJS'.7XPJL3Z!2>U/L/C9X,U6]M;:U\7>&+FYO91#;Q1:I`[SR'&$0!LLW(
MX'/(H`Z>BJ>M^(=/\-6JSZE?6>GP.XC62YF6)&8@G:"Q`S@$X]C6?)\3_#4,
M;N_B'0U2-MCL;^(!6R!@_-P<D#\:`-RBL32OB7X<UZ[,%CX@T2]G4;C'!?12
M.!DC.`Q/4$?45M+(KLP#`E#A@#]TXS@_@1^=`"T444`%>3_%?]M+P1\%?B'9
M^%]>M?B'_:NHS"VLVTWX?:_JMI>S&WDN?*BN;2SE@D<0Q2N55R5$;`X*D#UB
MO+OC_P#"[5_B!\6/@?JVFP0S67@?QM<ZWJSO*J-!;/X<UNP5E!&6/VB^MUPN
M#AB>BD$`V/A+^T9X4^--YJUKHMY<QWNBZB^EW%IJ-G+I]WYR6]O<,!!,J2X6
M.YA)RHVEB#@@BNQL]5M=0GN(K>YMYY;5_+G2.0,T+8SM8#H<=C7R!I_[!NK6
M7[0>M^/H?#'ANP\2W_QF7Q1#X@MQ!_:9T+^P(K!]TQ&_F02IY)W#!!V\EA0_
MX)>_L;^*_P!FSQ'9MXK\-^(-(U70/"2>&;[5'U+0I-+\1SI/&QNXDL;6*[G9
MVCDF$U^?.0W4RD.TCO0![Y\3/VX_AG\(_&>LZ#K.M:HU_P"&;>*[UY].\/:E
MJEIX=AD3S$DU"YM8)(+)3%F4FX>,"(&0X0;J]2&JVK&VQ<VY^V_\>_[P?O\`
MY=WR?WOE!/'89KY/\1_#7XI_!+QO\==(\*_#BU\?Z/\`&[5_[>TW5QJ]G8VN
MAW,^DV.ES0:G%,ZS/`ALEG$MND[M'*8Q&#&N_E'_`.";VH:-XAU?55\,:+K7
MB/1_%?PXD\/>)91;?VJ=.T>72$U*5)G/F0*8(+X-$&!D5Y%`?S<,`?5?PD_:
M*\+?'!&?PY<:E>1+=:K9&9]+N88/.TS4IM,O$\UHQ&'2Z@D4(6W,HWJ"GS5V
M3:A;I;/,9X1"C%6D+C:I!VD$],@@@^XK\W?$W_!.7XJZ]X$\3:=-X:TZY3Q'
M!XWMY;:34;5U8:K\0UUBU!Y5=KZ:SR,>H(V;58!#M?'_`/X)Z^,K7QGXE/@[
MP45^%]I\2K3Q,G@OPXVBP#7+(^%H[&66UM-05]-$B:@2YAN5A61HS+N5UCD8
M`_0ZBO+_`-B[X9S_``=_9A\(^&KBS\4::^E6TD:V?B&]LKO4;)#-(Z0R/8@6
MH5%951(`(XXU1%X6O4*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#S+
M]K/]K;P=^Q=\*X?%_C:YN+?2[O5;+1+98`F^>[NYEAACW2.D:`L<EY'1%`)+
M"L2U_P""@?PHM-3T'2?$/BO3_!GBCQ!IQU2'P_K\T=KJ<$(CN)29$#,H_=VE
MRZD,5=(79"ZC-=;^TE\!+/\`:7^$FH>$+_6M<T"TU%XVENM*^S-,51PS1-'=
M0SV\L4B@I)'-$Z.CL"O-?-&B?\$+/A)X>;1/LFM>,(4TCPW%X;EC:'2;C[6L
M:ZEMNEDFL9);.??JMS)_H,EO'N6+]WM3:0#UR\_X*8?`N/P@NL6?Q*\*:FL^
MD_VU9VD&HPQW5];&&[FC9$E9`HD2QNBC2%%(A8[@.:M6O_!1WX&36FL-/\4O
M!-G>>'8+6?5[";5[<WFF?:?*\E)(E=CO9IH5"KNRTJ`9++GS/XB?\$8/A1\3
M+_PG<W^K>/(I/"7P_'PZ00:G"JZG91Z?>6%M=7(,!WWEO%J%Z8Y%V*&N6+(X
M"A:6M_\`!%3X=>(/!VI^'+OQ?\0;KPW>:Q9^([72KAM,GM-/U6WE@F^UA'LC
M]H\Q[:+?#<^="1O41J&(H`]LT#]O'X+>*O'7A[PQIGQ3\":AK_BRUM[W1[&V
MUF"6;489TD>!XPK'=YBPRE!U;8V,XKE=$_X*G_`34OB-XG\(W_Q)\.>&_$WA
M3Q+)X3N]-UR[33[B>^1H%VP+(1YR$W,/S)D`-DX`)K@O!?\`P1B^'W@7]H3P
M#\1;#Q9XZL]1\`65I;0V.G-I^E66JO;^9MDNTM+6(R*QE8M$"(^`%55W*W*?
MM'_\$7K'QS+\1==\*^+==OO$/CFZU^^M-,\07L%OHFB7FM6]G;W=XGV6S^U3
M-$MC;O%%+*4RA#'G<`#[2\#_`!%T+XEZ==WGA[5[#6K2PO[G3+B:SF66.*ZM
MY6AGA+#C?'(K(P[,I!Y!KR+]IC_@IQ\`OV./'UKX6^)WQ2\,>#_$-[9C4(["
M]E<RBW+[!*P16V*3GEL<`GH":Y3Q]\0O`W_!%G_@F_\`:]5U&76;'P+ITGE&
M\G2WOO%VKSR23R<A2!<7=W++(VU2%,K'&!7\^_[,/[.OQ$_X+=?M=>/?B-\0
M_%]EX7\.Z6?[=\?^-=44S6/ARRVR"UM;2.8K']V.41QL2D:YD(;&UP#]\8?^
M"\?[']Q;2S)\?O`C10Q&9F\Z7&T9R1\G/W6P!R2"!3F_X+P_L?B(.OQ_\!2H
MSF,&*XDDRP3>0-J'^$?GQUXK\-OBA\!/V!_B-^R5\4->^%?Q>^)O@OXF?#NS
M<:!!XSN[(Q>-IHHE*"VL=A)AE?:F5V.AP[(P`W>B>!/^"5O['?CG]@_7?VA9
M/BQ^TMI7PV\-3+H]U)>Z7HWFZQ>B01,+.#R&:15DE*D/\YVXW'R\``_8B'_@
MNO\`LA3D;?C]X`P5#!C=.%;(0X!*8)_>)P.1N'%>_P#P!_:)\#_M3_#.T\8_
M#OQ/I/B[PS>RRP1:AI\OF1&2)RDB'H596!!5@#T[$5_.=_P38_X)F_LQ?\%'
M/B?XY\/>'_BE^T#I<FB)/KJW=_H&FVEE9Z*@@C_TRXW2H;D[F"[/+`7#;"8Y
M'/T'_P`$G/\`@I[^SA_P3?\`C'I_PO\`!'Q.^*/C7X>_$;Q"UG?7?C#3+/2M
M*\(3QQ-''?031IF>.>2.*%EW*J*!(<?Q@'[Q44B.)$#*0RL,@@Y!%+0`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7#?%+Q(;7X@^`-#;SO(US
M59GE$8C*M]FM9;A`X;Y@OF(C909W*@)`)SW-<E\9/AU>?$'PW;G1]2BT7Q)H
MURNH:/?RVJW,5O<*K+MDC.-\4B.\;A65MCMM='"L`#S31?AYX5^._P`;O&<7
MQ$TO3-?UCPUJ\<>C:+J]N+BTLK,6\$L-W;Q2J%F:1V9FF"MY<BM$&#1,3[58
M^&--TN,);:?8VZJ5($4"(`5SM/`[9./3)KPKXHZOJGQ"LX-%\=?L[^(/%\NG
MQNR:EI]WHMY8K-Q@VCSWMO=(794^9HH=O!9@%+#F]0T&ZU*1K4?!']HVVL['
MRHXHH?&VCI#*C"0D1G^W-RJF_##*'Y%VAAU`.D_:Y^$_@[X8^`]<\>^';'P[
MX-^)*9DTC6;6#[+/J.H.(HXXKA83&UXL@BBC:-V.44`,FT.O;^`?A?J_BGQ2
M/%GCLF6_A^72-$:6.>TT-=AC:8;44-<RJQWL2XC#,D;%<LWG/@'6)O@]KLLV
MB_LU?%B:^O8UMY-4?4_#ES=2QJLDVQY9M7WA5D54Z_,[(>5!=>P/[3GC#[-,
MP_9_^+QFC8*L?VWPW^^RQ4,K?VM@+T;YL,%894$,%`.0^(?@_4O@?X0UWX?0
MZO=V'@7Q[9S:!X2O8+&28>"KRZC,,5HZVY28VH=R\4@=!`J&-FC1(WIW@CPO
MXG^'^D6NDVW[.7@*UL+.T%I$=*UJQ2-43YA'Y;6R;5)"XP3\W)"]:U_&7[0/
MB#Q;\.]0L]:_9H^+>LZ?JMI);7VBS3^%YS<0N9(Y89%;5_*<&,;B`[*R2H`2
M^^-/(;WP<\V@6FFI\$/VO%T[3;6*6V2U^(UC93)E(AY(EBU])F958\.^U#`P
M4C=AP#TRZT;7;BPBN)?V9?"4\XCDN98/[6TMI!*7W;$)B"LS%48LQ49QR2*X
MOXH6G@7Q-\-?A;XT\#^!_#OAFYU;XE:'8W#1V-C:ZBBPZH8IHA+;,R,RO$V]
M%D;Y%E4X8%1D1>&=3M[JWB3X(?MA6L5K+,8KF+XFZ9N+L`"S`>(=SIEVVK)E
M`4^5-BH:M^(O$Y\0_!?2O`B?LK_M)Z1X7T6YM+S3/[-U7PY:W.GRP3!XY$E3
M7/M&Y9%$C,Q+,7));+``'3_M'_LVZGK_`.U)=>/+SX1>"/C7HUSX<L]#T^UU
M>2TCO_#LB3W;W'DB[C>(P7`FA,K*R29MXAMF4*(^5B^'[7]]]MD_8/\`"D6H
M0S--'//=>%BVY2S*X=69@Y:1B#CC,ISG&_BKOPAJ":9/;M\*_P#@H%M8.BR1
M_$ZR,JG##Y2-?SSOP"W`*`Y&,FU)H]W9D2P_#']OC?#YVW'Q`MI//`(^;;)K
M9');Y0P!&P\!<D@'6Z#\+_A;\1/%VA?#_P")'[*>@?#&X\56UR-"OC:Z)/$]
MU"K326]O<6,AFM[D1*\ZL%3*Q.5?<I%>K_L'^--=NO!_C/P)XEU6[\0ZO\(?
M$TGA$:U>2F6\UJU6TM;NTN;EL#=<&WNXDD;^-XV?C?@?/O@>1_A5X]B\6:=^
MS]^V)X[\7VUK<Z9HT7C'Q?::AIUF)1$&^6XUB2"!7W`-<>4\NQ9!\^T(?IK]
MC#X&:O\`!/X7ZI/XJ_LAO'7CK7;SQ7XH?2S)]B^W7+*!%%YC%BD-O%;0!N-W
MD;L#=B@#URBBB@`HHHH`\Q\0_M:^%?#/[4VA_"&X35V\4:]IIU.&>.TW:?`"
M+EHH99L_)-*EE>/&F"66UF/1:H_L_P#[;_PY_:*_M:UTGQ%I-CK^AZCK=A?:
M!?:E:KJUJFE:K<:9<73VZ2LZ6[36Q99&P-DL9.TMM'CWCG_@G5XN\3?$7QC\
M2K?Q[=Q_$2]\:V7B?P_9&X":#;6VGB*WM;2=1`9L268N4E,;#!OY]N026Y;2
M?^";'CG5M.;PSXCMOAO>^$/#_B'X@^)=,*ZA>23^)'\2RZP(K"^B%O']EMHX
M-7<2M%-.[M#'M"A0:`/?O$G_``43^!GA:U\-75Q\6/A_-IWBO69=`L=0MM?M
M)K);R.SEO'2699"D6(HNK$?-+"OWI4!ZC7?VLOA7X735FU/XE_#_`$Y=`D\G
M4S=>(K.$:<_GO;;9MT@\MO/CDBPV#YB,GW@17SU\._V.?C%X-N?#^L7&JZ'J
MDG@OQLGB70/#6K>,K_58K:U/AZ_TB6W?6);`7+`O??:%62WD"^45#?/N1X_8
M*\>^"_@/9^'_``OJV@VVIW7Q1\0>,O$266KW?A^?Q!I&HZMJU_!8?VM:P/=V
M\D37MD[R1)E_LCPAECD+T`?1FJ_M*_#G0](\.ZA>^/\`P39V'B\A="N9]<M8
MX=:)&0+5RX$^00?W9;K4'P'_`&G?`?[3.FZM=>!_%&C^(1H6HW6F:A':7<<L
MMI+!=3VQ+HK$JCO;RF-C@2(`ZY4@U\O_`+*W[!GQ2_9.CTN[L]-^%OC"YO\`
M2=2T75K'6->U%AH\4WB'5-5MVM;V6TGGNPT6I^5<+.D;S/:P.TS%<GZ%_90^
M%GBCX*Z3XM\/ZU8^&X]%E\4ZUKVBWVG:G-<7-[%J>K7NHLES;O;1+;M"+E(@
M$EG#A2<I@*0#UBBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`^3?^"S__``3AM_\`@IE^Q-J_@ZT6WB\;:#.NO>$;N=R(X-1B
M5EV.-RJR31/+"=YVCS0W50:_'#_@F-XZ^'-E_P`$N_VD_P!F?XA?%#0_V=OB
MUXJ\2M%=-XJWV<0B,%M"8'#!!M#I-&VS)17C^=OE<_T@U^=O_!13_@V_^$__
M``4"_:0N/B@WB?Q-X`\1:M;JFL)H\,$MOJLZ1^7%=,DJD),J?*67!;`)^8;J
M`/PK_;A^&?[,'P5^%7AOP5\%O%_BGXR?$M6W>)/&3L^F^&[DDF7R;2`A>OF1
MJ9$8A50$,S_*/H/_`(*^_M,_#3PO^P=^SQ^S'\%/&?AWQ/IW@J`Z_P"+M2\/
MW7FVUWJR*0Q>02%=TEW+<SR``$.8FCV#"C[6N_\`@SG^&LWG^7\:_B"@E<2*
MCZ1IK)&P<$841@$!0!@YYYZ$J8I/^#-WX:RVK1/\;/B&2TCMO72[!)`"Q*X=
M4#*P4E25(4@M\HW-D`^/_P#@G[^U'\+_`-@S_@C3\?\`Q'I_C[0KW]H'XQ-=
M:%8Z+$L;ZUHMB&GM86EA5%FCPS7<[$E\`PG:7^1OFK_@DU_P34UK_@I;^U'H
M7PV@MM4TOP/I]L=0\9ZA;W2HVDZ26V!89"K(T\[*D<1*L'Q)*8\(S+^J6J?\
M&</P_P!6M467XX^.]\<;1H%T6Q2&/<4+$(H']TXW$XSWQ7Z$?\$Q_P#@FMX.
M_P""8'[/LO@GPO>WFNW^IW\FIZSKM[$L=UJTY^5"ZKD*L<2I&J@G`3/4F@#Z
M`\.:!;>%/#UAI=DC1V>FV\=K`K.7*QHH502>2<`<GDU=KYTUW_@I/X3\.?M`
M^,/"EYH/B"T\%_#F,Q>+_B/=RV5IX6\-7WV9+I;*>:6=93)Y,L662-E5YXD)
MRQV]7X,_X*!?!/XB6_@J31/BAX,U+_A8LGD>&TAU)#)JTO[P&*-,[O,!AE4H
MP#!HG4@%2``>P45\R?$K_@JAX'^"OQ]U_P`)>--#\2^%O"?A_P`/6_BB3XAW
MSV1\*W5A/Y:1R13)<-.2T\GD!3"-SHQ&4VLW<>(_^"A'P2\(>#E\0:I\3O"6
MGZ.;*YU(W5Q>B-8[>VNX+.XE<'E%CN;F")]P&UY5!ZT`>QT5X1I7_!4']G;6
M_`\OB2U^-7PWET:W-FL]Q_;D"FW:\9EMED0MO1I#')M#`'$4IZ1N1L_#7]OO
MX+?&+XN6_@+PM\3O!VO^,[O31K$.C66HI+=R6;0PSK.$'.QHIXG!_B5B1G:V
M`#UZBOF;1/\`@JS\-+?XN^-?"7C./5OA@_@[Q9:>"H]1\6-:V-GKNJ74?GVT
M-IB9I&$MN8IU9T0>7*N=K!E67XY_\%7?@M\`_CAH?@?6?'?@NWN[G4[C2]>N
MKKQ#:VL/A66*R>[070=LAI`HC51_&V"0>*`/I2BO%M=_X*-_`7PQKOC;2]1^
M+WP_L=3^&\$MSXGM)]:A2?0XXI$B<SH6W+B26),8R7E10"6`/(W?_!5SX1:'
M\0?%%MK'BC0-(\"^'=`T#7(/&LVK0/H^KC6+F]MK>*W="=VU[)MSYP"_.`I)
M`/I>BO!?B?\`\%&OACX/U[4?#?AWQ3X2\9^.])ETHW7AFR\26-M?16U_=6L$
M=S^^D52@6[BD"J2T@*J@9W16Z?PS^W%\&_&4]G%I?Q2\`WLVH:U-X<M(H]<M
M_,NM2A!,MG&I?+S(`2R*"0`:`/4Z*\F^/G[:?@3]F7XH^#_"_C34?[#/C+3=
M8U:'5;J2*'3;"WTN*"6Y>XE=P4^6X3;A2#ALE>-VMX,_:W^%WQ%\0^&=)T#X
MA>#M:U+QG8W&IZ#;66K0SR:S:V[F.>>W"L?-C1P0S+D`J?0T`>AT444`%%%%
M`!62_C2S1F!AU;Y':,XTJZ/*M*IQ^[Y&87P1P08R"1+&6UJ*`,*\^(FGV%I?
MS/;ZZR:<D3RB/1+V1W$C%5\M5B+2D$?,(PQ08+;00:?<>/K&UU*:T:#6C+!/
M%;,R:/=O&6D9%4K((BC(#(NYU)5`'+%0CE=JB@#"M/B+I]ZEJR6^NJ+Q"\?F
M:)>QE0/*^^&B!0_O4X?!.)./W<FV5?'-DUW'"(-8WRVYN03I-V$"@@8+>7M#
M_,/D)#$9.,`XV**`,27Q_80B7,&MGRBP;;HUXV<*['&(OFX0XQG)*@9+*#/;
M>,+2[$>V'5!YK,J[],N4P5)!SF,8'!P3@'@C.1G4HH`R;?QK9W,%K(L.K!;M
M"Z!]*ND90'"?.#&"ARPX;!(RV-H)#$\=V+RQ)Y6KJ9A%M+Z3=*H\PH%!)CPI
MRZ[@<;/FW8VMC9HH`PU^(>FO%<.J:JPM9'B<#2KHL60$L%'EY;@'&T'/&,Y&
M9;GQS86EG).ZZCY<2N[;=.N&;"F0-A0F3CRVZ#NG]]-VO10!@W'Q(TNUN+J*
M0:HKV4D,4I_LJZ*@S,%0@^7AER1N920@R6*@$U+;>/=+NI0BS7`W*KAGM943
M#;/XBH&1YBY&<KSG&UL;-%`!7F'[8G[3%M^R-\!-3\;W.F?VL+.YL[&*"2^B
ML+5);JYBMHY;FYD^6WM4>57FF*N8XU=@CD!&]/KE?C1X0\1^.OAY>Z;X4\30
M>$=;F*-!J-QI,>JP*%8%HY;=V421NH*,%=&PQVNIP0`<!\&/VLY?$.C>&AX^
ML_!_AW5?&VNOH/AI_"WB5_%6CZ_,MC/?$0WBVMNR,L-I=EA-#&H\CY68L!7#
M^//^"JO@#P/\4/"MJHU;6O`_B/P_XDU1]=T?0]4U2XL[G1=6L=-N86M+:UDE
M\I9+FY9YR%2,6A/S*X8<UX?_`."6VM^#M+L=<T+QUX,\/_$G3O':>/(+G2O`
M9M/"<5P-'N-&:%=%2^#@-974Q,IO#*9MCEBB+$(['_@F#XV\$:3X-?PC\7])
MTO7O#NC^,="O]1U+P8VHKJ-OXCUJUU6X>.(7T0@FA:U5$),L?S%C'M'ET`>H
M>-/^"FWP4\!>+I-%O_%>HRW,)M%EN;#PUJNH:="]W;PW%FCWEO;/;(]S'/"(
M$:0-.\JQQAY#LJ2+_@HC\-M1T7PUKEKK(MO#6MWFLV-]>ZU9WNBW&ARZ7:3W
M5Y'<VMU;I-`\<=M*S)<+"0BEAN!4-S/@O_@F9HOPV\,ZIH>A>(KJTT>Y\0^"
MM8LH9+3?)90>&DTJ.&V+K(OF&9-+4,^%"^<?D<##-^(/_!.:7QOK.J7P\7V(
M;4O$/B+7FM;_`,/+?6+C5=#?2A!+`TP69(LK(V[B4;X]J!]R@'6R_P#!1CX5
MVW@Z+6IKSQM`MQJ3Z5#IDW@'7X];FF2$3R,FF-9"]:%(B':=83"JD$N!5OQ)
M^W;X!\!Z?X@O=?O[JTMM(UVVT"R@L--O=4U+6+B?2K74TC@L;:![F2807!<Q
M1QNRQQ&1MJYV^"O_`,$J?':?"9M&3XH>#9M7&O3:Q8M<>%=8?3/#2R6HMC_9
M*_VY_:&GR_ZR5C%?^6[RR#RU#9'<:G_P3O\`$6A>+%\8^%_B1;KX_P!.\2P>
M(M/U3Q%H!U.WGQX;L]`NHKZ**Y@>=IH[0W`>*2#9*Z_*ZAQ(`=WXP_X*-?!?
MP)8Z1=:CXWM_LVM:1'X@MYK73[N\CBTUY3";V=H8G%O;I("LDLVQ(2#YA2O1
M?C!\8=#^!?@>?Q#XA.KG3K=TB*:7HUYK%W([G"K':V<4L\A)[)&QKYVT/_@F
M%)H/PA\9^&(O'CFX\;?#2^\#7=\^D9\J^O;K4KNXU$1K,H,0GU*4QVPVE$4+
MYS9R/4/VUOV;=<_:>^&ND:-H7B>V\/3Z5K46J7%M?VMQ=:5K\"PSQ-8WT-O<
M6\LD!,RS!5F4>;;PE@ZAD8`H^+O^"COP8\#>"-"\1ZEXT2/1O$=M=WMG<0Z7
M>W!6"TG2WO)IDCA9[>.VFD5)VF""$D^84P<5/CO_`,%"O`_P:^)OAKP5:3_\
M)'XKU_Q+H_AZ:SM%F,.F?VC(NR2:Y2)X4<0MYRPNZO(NTC"L&KSGX,?\$K[C
MX3_"IO#DGC;2[N9_"WCCPX;BQ\-G3X$;Q)K7]J^9'`;F0)':DM$L6X[P0=R_
M=HB_X)L^+]%\:V\>D?$70K7P3<>-_#_Q!U2PNO#<ESJ<^H:;;:?:O;P70NDC
MBMI8].B8;X9'1W<!BNT*`?8%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`'S3\9_\`@E-\,OCAX^\9:YJ.I?$3
M2[7X@0(?$&AZ/XJN['1]1OH_*\G4VMD;:MY$8+<K(N%S`A96);=QW@C_`((:
M_!/P/\3="\8B7QEK7B/3K^35-7O]:U*+4I_%ETTHF6:_>:%FW)("R_9S`#N*
ML&4!1]CT4`>`^/\`_@FC\*?'WC'2]8_L:30UT6'1+:QT[1EALM/M8M*UG^V+
M=$@6/:@>Y++)MQNC=U&W<Q/)7G_!'_X8ZC\3?$'B>YUSXAW+ZWJ,FJ6VG2ZV
M&L=`EFUJRUNY%BGE[H4GOK"!W4LV`9`GE[B:^JZ*`/C#Q+_P0S^%.MV6E)8^
M*?B?X9N]!M;.UTR^T/5[:QNK`6TVJ2AT9;;!:0:Q>QR;PP,;@`*=Q;MO@A_P
M2A^%WP`\=^%?$.AS^*I+[P??)J-BMWJ"21-*F@VVA+O`C!*BUM5<*"%$LLK`
M!6"#Z9HH`^3_`-HW_@C7\(OVG?BK?^,M?E\36^M:MK7]LWOV6>U>VNBUA:Z?
M-;M#/;R)Y,MO9P!B`)0RETD1B34\'_!('X86.GZWI=MJGC6#PSJU_K6J6^@_
MVA$]CI%QJUC/9WSVQ,)G4.+B24!Y6$<H!3:N5/U310!\A7O_``18^%LME;+:
M>(/B)IE[I\]S>6-]:ZG;K<6-S-/HMP)X]UNR%XY=!L60.K)S,&5A)@<_JO\`
MP01^$%QX=M[/3/%/Q7\/7]K906<.LZ?XA3^TH?+;5S)(LDL+JKS#6[]9,)@J
MR!0FT[OMVB@#\RO"/_!O58G]IKQ`VK^(3I?P*TZUC7PAX<TC5;FYO;>X-WI-
MY++,+N.1(6\[2(-S))+YP8;1;>7A_8?A]_P0S^&7P=U'P=>>#_%/CGP_<^!?
M$<OB;37MSIR-<3&*.&"WNI4M$GGMX8XR@7S5>5)'2:296(/VI10!\T_&W_@F
M=X?_`&G/AC\.=&^(/BWQ=K>M>`M'N-+EU>.XCCDUMKJ&".[EN$9'4F3R`0!]
MS>V.Q&='_P`$IO#GA3Q9J.M>!_B/\4?AY?:Q87FGWXT2[T_9=1W&IW>I`@S6
MDDD#1SWLZJUL\1,9`8LP#CZGHH`2-2D:@L7(&"QQEO?CBEHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`KY:\%_MQ^)_#6I?$I?%VB-XJ;1O
MB?\`\*]\+:9X5T=;"^OBVGP7T;2O?7X@<[9RAD5XDS"6P-Q6/ZEKPCPS_P`$
M^_"N@>(M7U*Y\0^,M9DUCQ_#\2'BOKJV\J#58HO*01B*!"(?+6)=A)/[B,[L
M[BP!F6'_``4P\$6_A34=5U_1?%OA6/1O#WB3Q!?1ZA!;2-$/#]^UCJMJA@GD
M$MQ%*%($99'25"KDY"Y'C/\`;^U_P_\`%'PYH6D_#KQ%XCGUKQ;!X>OM(A_L
M^SU/15E\*W&N"-VGOUADN-\00_,D:JLH#.PC,G8^,?\`@GS\/?'ND^%[/5$U
MFXC\)>.+WQ]:'[8%,][=WMS>SV\^%Q+:-+<G]R1@K%$"25R9_BA^Q+I/Q"U_
M5M<T_P`7>,_"'B;4?$MKXJM]8T>6S,^E7<.EG2CY,=Q;S0,DEFTJ,LT<O,I8
M8*IM`.&^,O\`P5`T'X:>-?&'@VU\+ZI=>--"TS5[G2;5]:T1X]8N;"QEO!"8
MH;][NV62*%V5[J"%<(<D$H&GT_\`X*)P:1H/AW6?%7AOQ#X<35_!8\2G19+"
MWGO[F:6]L;.UCAEAO)(0;B:\1(XGP?G4N\6UEJ_IO_!-+PG9_$:;6+CQ7XYU
M#03JVM:S:^$YY-/71;&XUB*ZCU`J([1+F02F\G<":>0QDA4*QC93M+_X)N>'
M!X/TK2M;\:>/?$UQH'A]_#6EZG>R:?!>Z?:K>V=[:,C6UI$K36DUA;&*1U8Y
M5C)YA8F@":U_X*(Z->3Q:3'X`^(Y\;GQ4?!USX2,.G#4[&^_LIM74R2F\^Q&
M%K%1*)8[EU^8)D.&5>A\<?M67%[^PKJOQD^'?A;5/&5V?"<OB71?#K1R17VH
M2"W,JVCQQ++()MPV-&BNVX%5#'&:GPK_`&%]$^'6M:)KFI>*_&?C+Q;I7B.;
MQ5=:[K-S;?:=8O9-*DTD>='!!%`D:6;A5C@BB4-&&.69R_4^%/V;M/\``'[-
M=M\,O#VO^*-#L+#33IUGK%I=1#5K/.2)TD:,Q^:&.[YHRAZ%",@@'C/P8_X*
M&65YX4U;Q!XB\9^!/&VA6FKZ'HLLGA+2;S3=0\-7.IW7V5!JEC>3/+;P+))#
M_I#%#M$S-$@C)KH]<_X*4>#[+Q8FAZ5X<\8^(]3N-1UG3[2*R6PM_P"TAI,\
M%M?36S75U")UCN9C"$C+3,\$VV,JH8UO&7[".HZA\&?BQ:W'C;6_B5X]^(?A
M"7PI;ZKXQ-I9P6D*QW/V:/;IEI`J(LUS)*TBQM*6/#*%15H_'3_@EKX7^._[
M._AGX67OBSQ/I_@O1=*;2-0LTM--OWUM7*-)=/+>VL\D-XSJ[?:8620-/(P.
M_8Z`$5G_`,%-['P[;>/+CQAX$\2^'+;PQXWE\$Z/*]YIBIXCNEY1(GENT6)S
M$LDY-P8HEB"GS"QVU=G_`."IO@2YT;3[W1_#OCGQ(+K1M;UZY33+2T?^S+71
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M+!(-J!O-<ZC*').TA$PJ\Y]*H`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"JVLZ
MHFB:/=WLB2R1V<+SLD2[G8*I8A1W/'`JS10!\5?`?XX_'/\`:7NY/$NA:WH.
MFV\=Q`$TJZU.T&F"6XTN#5(;1H5T^2[FB\BXAB-U'?(QD,LRVS0QJDGT[X9\
M>ZI\;/V==(\4^#IM,T;5?%F@VVK:2^JVKW]I:O<0)+&)HXI8FD4;P#LD0GJ#
M7BNH?\$E/AI=?%VV\46]YK.FVEG;26$&CV>G:/&EM921R1O90ZC]A.K6]H5E
MD4007T<:(QC15B_=U]&:KX)T[5?!DGA\1W&GZ6]L+-(]+NI=-DMX@`H6&6W9
M)(<```QLI&."*`/C_0/VKOB;XX_8<_9T\:W]]XBTP^/+2"X\<^(/!OA(^(+[
M3F;3YI(Q;V,45V1'+>")#(L,X5<+\IE$L?F/C?\`X*1_%E_V;]"^(5R_B7P?
MH]A\/+WQ+%JNG_#N]U>S\5:S9W-W!);7T0B>73+1X;>WN<.86VWC#[0!;ON^
MT/"7[&/@/P%\%],^'VB)XPTGPGH\Z3V5I:>,]9AEMPL?EK"+A;H3_9]O_+`O
MY1/)3/-6_%7[(W@#QEX6\+^'[S1[R+PQX.M(]/TW0++5[VQT4VL8B$=O<6,$
MR6UW"JP1JL=Q'(@4,H&'8$`^<[']O3Q5KO[3NN76LV?C/PK\*O"OBO0_`JM8
M:3IEQ;S:KJ5CIUPO]HR2SF^1&GU6UM46VM5"/MD>5E=EB^I/B5\=_#WPE\4^
M&-'UE?$1O?%]W]BTXZ=X<U'4[<2^9%'_`*1/;0216J[IT^>X:-=H=L[8Y"N%
MXE_8X^'/B_XK/XTU'P_)/KD]_8ZM<J-3NTT^^OK(*+.\N+%91:SW,'EP^7-+
M$TB&W@(8&&/9Z=0!Y'^V;XEU3P)\);CQ#9_$8?#BPT5))[JXAT.'5KS4Y-N(
M+2WBD)WR22800QQO-,SJD95R"?G+XL_M=_'#P#\+=4\6>()=$\(ZQ\(OA)X;
M^(7B_P`,VUA%<1:WJ5Y)J']HV'G2.S6\,2Z9+'$R'(>?<SND>&^I_CM^RYX-
M_:1NO#EQXKM=<ENO"-W+?Z1<:7XAU'1I[*>2%H6D62RGA8MY;NH+$[=Q(P>:
MPO%O["OPW\=SZ-)K.G^(M4;1[6WL3]J\5:K-_:UO;SM<00ZCNN3_`&@D<SNZ
MB[\W!=QT=PP`I^)WC#3/VZ+7P7>W/A^3P7K7@V]UO38+>V==1AN;6[L()3/(
MSE61A>#8$08PVXYVYX_]F+X@_$6?]J#Q?X+USQQI/Q-\/^&]&@EU?5[/0(]*
MCT+6Y)F*Z;&8Y9`^;;$KQ.7E@!A+R$7"`>J7W[.'A;4?CM9_$F9?$3>++"QF
MTVWE'B34ELHK>54$D8LA/]DPQBC8_NL[XT?[ZAA@_L[?L4^`?V4XX8O`\?C'
M3[*VAGABL+[QKK6K6$?GSFXE<6UW=RPB5I69C)LW_.PW88@@'K%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`>4?MV?%#Q1\%/V-/B?XM\%6S77BSP[
MX;O;[2E6S-[Y<Z0L5D,`(,H3[Y0'+!"!G.*\)\;:OH?[$'P?N/B%X/\`BSXK
M^(WB+Q);6=I;6_BKQS+K&C7[WVJ6-D=::W=V\BULWO%EE6Q,$0A+(0#Y;)]F
MUYMX,_9`^$'@*^\3S^'OA=\-M%N?%R/;^(I-.\-V5L^M(_S-'=E(P9PV[)$F
M[.[/>@#Y9\8?\%%/BMX-U:[^&RV7A;Q'\1].\?2>"W\2Z'X=FGT>\9=!CUQ4
MCTR748W2Z,4HMS`VHD#RWF\S_ED/;/AG\??%?QX\$^$?#/BGX8?$;0+[QKX=
M2;6_$>@WUE!I.@W+0.942Y2]^UHXD0JACB=E+IEN&8=X/V._A(/@@GPR_P"%
M7_#T_#A'$@\+'P[:'1=XD\W=]D\OR2?,^?.W);GK7;>&O#>D_#_PQI^CZ/8:
M=HFC:7#'96-C9P);6MI$H"1Q1QJ`J*!A550`.`!0!\(^$M=\4_LQ_!WXG?$/
M1O%GC#QSXBT'XG1^!=(TWQ9XIU34=)6SNM>T[3U$L>YRLL:7$A$X5RF=S!@&
M2O6[W]L;QS\.[#Q5IOBB+P1>>(O"WCGP3X1>2PCGMK6\36[W2K>XE2*29Y`R
M)?3&($E<Q`$MM?'T)=_";PK?Z1=Z?/X9\/S6&H:DFLW5M)IT+0W-\DT<Z73H
M5PTZS112"0@L'C1@<J",/QA^RQ\,OB%\5-/\<Z_\._`^N>--)2".QU[4-#MK
MG4K)8)A<0B*=T,B>7,JR+M8;74,,$`T`?+_@;]L?X\?&'QQHECH=S\'M"L?&
M?B7QKX:TD:CHFI7EQIQ\.ZS<V0N9?+O(UN/M$5JZF%?)\IF$HEE`^SU@Z]_P
M5>\<:E\)_A7XZ\->'?#U]9Z[X5\->)/&&A"TEF;2AK%P8$V:DUS#%$@:.?8/
ML]Q(_E@M&BD,?MC0?A!X2\+36$FF>%_#NG2:5/>W5DUKIL,+6<U[*TUY)&54
M;'N)7>25EP9'9F;))-<=KG[#/P5\3R>'GU/X1?#+4F\)6,>FZ(;OPQ93_P!D
M6L;%HX;?=&?*1&+%57`4LQ&-QR`>7?##]L3Q_P"+?COIMKJ6G^"H/`^M_$;Q
M!\.;.&W^U#5TFTZTO[N.\>1SY+!UTZ=&A5./,1Q)\K1U]25SVG_"3PMI-U!/
M:^'-#MY[75KC7H9([&)7BU&>.6*>\4@9$\D<\R-)]YEE<$X8BNAH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@"AXI\+:9XX\,ZCHFMZ=8:QHVL6LMC?V%]
M;I<6M];RH4DAEC<%7C=&965@0P)!!!K\Z])\&Z5^RO\`!W]J+QS\)?A[X,TO
MQIX.^*":)IVIVVA6T4OAK1YX=!34)H6CMY6A@M;6>ZNB@BDC!A9VAD!,9_2.
MB@#\[],_;;UP>"O!%QXH_:.\$^'?AIK7B#6[>Y^)WAK6-)UJTC%O9VLMGIDN
MJ7.FPZ<)&EDOOWPM,%;.*'<9W9C9T/QYXF^'/Q>\:^.O#?Q)U>^TC4_BWX%T
M2\M9=+L18^*;?5=&\-6,EU/_`*,LL<[),DB&"6)495!C*DJWZ#,@<88`C(/(
M[CD4M`'YW^)/VK?C=X"\"_\`"5>'?%^I_$?6?$ME\2X=)\+SZ/IWD&]T2XNU
MTK[*D%O#</Q;*DBR32>89,#!*D5[7]H^Y^->HSZ/I?Q0B^.?@'P[XR^&EWI?
MC:"+3PJZU<^('74=+=K&&*!O(MH;.7RPOG0F]42NP(Q^@K>--'2]U2V.K:8+
MC0XDGU&(W2;]/C=69'F&<QJRHQ!;`(4GL:A\)^/_``]XTDFBT+6]&U9H(8+N
M5+"\BG,<5PGFPR,$)PLJ9=&/#CD9'-`'YS>$/^"BOQ5UGP+=:AX=\90>._%T
MWPQUKQ'XX\-0Z5:S2?!O7XKC3UM;)X8(4N3Y2W.H*;>[\R:Y_LWS$*J'![7P
M=^TSJOQ`UW2H+'X@2_%3PQI/QRT;0-*UZ_T_3Q=7-G)X8BOG'^C6]O#DW4S;
M)EC7A]H)`K[E\9VVCW&@7=EJ]S'8VNNC^S7D6\:REG:8>4L<<R,KK*V["%&#
M@XVD'%<WX)^''@C]E/X=ZQ+!<MHVAI,^L:QJWB#7;B^ED=8HT:YNKZ^EDE<K
M%#$N^60[4B0`@*``#\^OAS_P4,^*OB_X"ZOK=[\:?A%I6L_V'I.I:W8W_B?3
M+34O!VH2:G;QWNGE'TX1Z<S1O/:Q+J0N2DZ1[Y&'F.OV1^P_^U/HOQI^#'@U
MIO$^JZ]KOB<Z[+82ZHM@]YJEMINIM:3W*OIJ_8I;=#);*EQ#MCE2:!L!I-M>
MVWMC8;)4N(;/;J#A)%D1<7+8P`<_>.!CG/`]JI_\(!I'_"<P>)/L2_VU:Z>^
ME07&]OW-L\B2/&J9V*&>.,D@9/EH"2%``!\B?MC_`!+\,?#?]O2"_P!,UKPO
M:?$?2/@EXQUBTM9;R$ZAY\$NFM9RFW9\LJH+\KN7&T7&.!)CD/%O[6OQ5^#W
M@Z\M]0^(4E];ZIX;^'NN7GBW6-&L4A\&+K6K7MIJEQM@@B@^SI;VRM%]H+^2
MY9Y'EC!4??TEG#-+O>*-GV[=Q4$XYXSZ<G\Z:^FV\L,D;6\+1RQ^2ZE`5=.1
ML([KR>.G)H`\N_9L^-GA?Q1X:T/0[3XMZ-\5M:U*'5;ZTU:VDL_-U2UL[\6L
M[[;0+`?L\DT%O(Z*H,@)VJ25'J]066E6NFP0Q6UM!;QVZ>7$D<818EX^50.@
MX'`]!4]`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%-FE$$3.P8A`6(52Q
MX]`.2?84ZB@#\XO@W\'_`(N^'_C)9?&R[\#2:&?CU!KUOXNBM;F_G\16\-W;
M&;P_]MM&M%%HVG6UA;6)`E(66]F;:K2,*]K_`.":GPZ\0>`_$&O?VYX;UK0!
M+X%\#VJ?;;-X(S-!I4D<\",V-SPO\KC&5+`'L!]944`?$]W\-?B=<^#;;Q%<
MZE\1]5UO4?CFL+:;J'G26NF^'+;Q?.8GAM53"0&S2.07$@),)0AQ&(U'SY\6
M-0^(OCWX`>-_A_>K\9=9^(?B7]G[Q+=^,-(U6VOYX;SQ.9=*@4Z9:,K1M"DD
MMVD8LE,#1LH42DMC]6ZX[X:_L\>`/@QK6K:EX/\`!'A'PKJ&O%6U*YTC1[>R
MFORI8KYK1(I?!=R-Q/+L>K'(!\>_M3?!_7-)\1S6VHWOQCO_``/X.^(WA[Q#
M!?64^KZGJ%M;SV-Q!=-;/`LES*BW#1EHXA(L(D/RQH7QVO[,GBWQM!^W;XKT
M74YO'WBO0+D:I=0ZK?6NLZ19:)`MS&+6UEM+VW2RGX:6.&ZLIBTJ0%WC;+R)
M]?5@^`?B;HOQ.AU:31+MKQ-#U2YT6])ADC$5W;MLEC&]1NVMQN7*GL>#0!O4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%>5_MT?#_7OBS^Q+
M\8O"OA6WDN_%'B;P/K6E:/!'<+;O->3V$\4""1B%C)D=0&)`7.21BO5**`/S
MG_;X_P""<>KZA\2K.+P)X&\6:MX1U#12FG3^%[C2)-6\)^(S=22RZR)M7N(V
MBN)E:W8WMN[W"M:-N5_-(<^(/[(/Q9UK]J/XQ:AX+\`'2]5\::5X@AB^('B(
M::M]:/+I_DZ?#INJ6MXU_P#9GEV@6US9A;11*R292+SOT8HH`_.+X*?L*^(+
M_P`&P:.WPP\=>$/#-]XZT#4-4\-W[:!HME':PVUTE[<V\>C7KAE?S(1.TC+)
M<%0#$PW!O5;;]C+QWX?_`&DKGPWX=4>'_@_X=,_C?PG>QWX:.WUV;3O[,BTR
M2W'[TVMNWGW^2=K/<Q*"?+95^R**`/R_^#O[&?Q.\,?LZZ]I5]\-?'L3,?"L
M'C7PVD^B6$/C^*UO9FU5K62WOW^US3PE?/FOG@>]@,<+Y8O'']*?L!>$/%'[
M.O@5="_X4YK/A#1O&OQ#UZ^2P6]TTCPEITJ2W-O/<+!<2*RR/&L02)G9&F3(
M51Q]644`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
0`!1110`4444`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
